

# A decade of fragment-based drug design: strategic adva

Nature Reviews Drug Discovery

6, 211-219

DOI: [10.1038/nrd2220](https://doi.org/10.1038/nrd2220)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Dynamic Covalent Chemistry in Fragment-Based Drug Discovery. , 2004, , 1-9.		0
2	The SeeDs Approach: Integrating Fragments into Drug Discovery. Current Topics in Medicinal Chemistry, 2007, 7, 1568-1581.	1.0	89
3	Solid-state NMR spectroscopy as a tool for drug design: from membrane-embedded targets to amyloid fibrils. Biochemical Society Transactions, 2007, 35, 985-990.	1.6	16
4	Structural biology approaches to antibacterial drug discovery. Expert Opinion on Drug Discovery, 2007, 2, 1085-1101.	2.5	6
5	Efficient Synthesis of Maleimides and Carbazoles via Zn(OTf) <sub>2</sub> -Catalyzed Tandem Annulations of Isonitriles and Allenic Esters. Organic Letters, 2007, 9, 4057-4060.	2.4	49
6	Crystal Structure of Human Arginase I Complexed with Thiosemicarbazide Reveals an Unusual Thiocarbonyl $\frac{1}{4}$ -Sulfide Ligand in the Binuclear Manganese Cluster. Journal of the American Chemical Society, 2007, 129, 6388-6389.	6.6	57
7	Tethering Small Molecules to a Phage Display Library: Discovery of a Selective Bivalent Inhibitor of Protein Kinase A. Journal of the American Chemical Society, 2007, 129, 13812-13813.	6.6	64
8	Chapter 28 Fragment-Based Lead Discovery. Annual Reports in Medicinal Chemistry, 2007, 42, 431-448.	0.5	21
9	Fragment-based drug discovery using the SHAPES method. Expert Opinion on Drug Discovery, 2007, 2, 1555-1566.	2.5	18
10	Drug Discovery in the Post-Genomic Era: Systems-Based Drug Discovery. , 2007, , .		0
11	Targeting enzyme inhibitors in drug discovery. Expert Opinion on Therapeutic Targets, 2007, 11, 967-978.	1.5	95
12	The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family Members. Clinical Cancer Research, 2007, 13, 7264-7270.	3.2	330
13	Fragment-Based Ligand Discovery Meets Phage Display. ACS Chemical Biology, 2007, 2, 779-782.	1.6	9
14	Fragment-based approaches to enzyme inhibition. Current Opinion in Biotechnology, 2007, 18, 489-496.	3.3	98
15	Fragment-based screening using X-ray crystallography and NMR spectroscopy. Current Opinion in Chemical Biology, 2007, 11, 485-493.	2.8	151
16	Discovery and Design of Novel HSP90 Inhibitors Using Multiple Fragment-based Design Strategies. Chemical Biology and Drug Design, 2007, 70, 1-12.	1.5	107
17	Integration of fragment screening and library design. Drug Discovery Today, 2007, 12, 1032-1039.	3.2	143
18	A Sorcerer's apprentice and The Rule of Five: from rule-of-thumb to commandment and beyond. Drug Discovery Today, 2007, 12, 995-997.	3.2	50

#	ARTICLE	IF	CITATIONS
19	Nuclear Magnetic Resonance Fragment-Based Identification of Novel FKBP12 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 6607-6617.	2.9	22
20	Characterization of an exosite binding inhibitor of matrix metalloproteinase 13. <i>Protein Science</i> , 2007, 17, 66-71.	3.1	41
21	Structural genomics of protein phosphatases. <i>Journal of Structural and Functional Genomics</i> , 2007, 8, 121-140.	1.2	148
22	Perspectives of biomolecular NMR in drug discovery: the blessing and curse of versatility. <i>Journal of Biomolecular NMR</i> , 2007, 39, 87-90.	1.6	45
23	Drug discovery beyond the "rule-of-five"™. <i>Current Opinion in Biotechnology</i> , 2007, 18, 478-488.	3.3	278
24	An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. <i>Journal of Computer-Aided Molecular Design</i> , 2008, 22, 693-705.	1.3	283
25	CONFIRM: connecting fragments found in receptor molecules. <i>Journal of Computer-Aided Molecular Design</i> , 2008, 22, 761-772.	1.3	33
26	On the relevance of defining protein structures in cancer research. <i>Clinical and Translational Oncology</i> , 2008, 10, 204-212.	1.2	0
27	Structural insights on the pamoic acid and the 8 kDa domain of DNA polymerase beta complex: Towards the design of higher-affinity inhibitors. <i>BMC Structural Biology</i> , 2008, 8, 22.	2.3	22
28	A computational protocol to fragment-based drug design at PDB scale. <i>Chemistry Central Journal</i> , 2008, 2, .	2.6	1
29	Fragment approaches in structure-based drug discovery. <i>Journal of Synchrotron Radiation</i> , 2008, 15, 227-230.	1.0	44
30	Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases. <i>ChemMedChem</i> , 2008, 3, 435-444.	1.6	409
31	On the Art of Compiling and Using 'Drug-Like' Chemical Fragment Spaces. <i>ChemMedChem</i> , 2008, 3, 1503-1507.	1.6	231
32	Theoretical analysis of the competition ligand-based NMR experiments and selected applications to fragment screening and binding constant measurements. <i>Concepts in Magnetic Resonance Part A: Bridging Education and Research</i> , 2008, 32A, 341-372.	0.2	36
33	Sensitized Detection of Inhibitory Fragments and Iterative Development of Non-Peptidic Protease Inhibitors by Dynamic Ligation Screening. <i>Angewandte Chemie - International Edition</i> , 2008, 47, 3275-3278.	7.2	64
35	Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7450-7456.	1.4	60
36	The discovery of small molecule chemical probes of Bcl-XL and Mcl-1. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7443-7449.	1.4	38
37	Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2990-2995.	1.0	59

#	ARTICLE	IF	CITATIONS
38	Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2840-2844.	1.0	37
39	Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3978-3981.	1.0	66
40	Fragment-based activity space: smaller is better. <i>Current Opinion in Chemical Biology</i> , 2008, 12, 260-268.	2.8	56
41	Structure-directed combinatorial library design. <i>Current Opinion in Chemical Biology</i> , 2008, 12, 379-385.	2.8	21
42	Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening. <i>Current Opinion in Chemical Biology</i> , 2008, 12, 340-351.	2.8	43
43	Epigenetics and Complex Disease: From Etiology to New Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2008, 48, 257-276.	4.2	152
44	Computational chemistry approaches to drug discovery in signal transduction. <i>Biotechnology Journal</i> , 2008, 3, 452-470.	1.8	21
45	Characterization of <i>Aquifex aeolicus</i> 4â€diphosphocytidylâ€2 <i>C</i> â€methylâ€dâ€erythritol kinase â€“ ligand recognition in a template for antimicrobial drug discovery. <i>FEBS Journal</i> , 2008, 275, 2779-2794.	2.2	33
46	Perspectives on NMR in drug discovery: a technique comes of age. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 738-745.	21.5	373
47	Microfluidics for drug discovery and development: From target selection to product lifecycle management. <i>Drug Discovery Today</i> , 2008, 13, 1-13.	3.2	290
48	The design, structures and therapeutic potential of protein epitope mimetics. <i>Drug Discovery Today</i> , 2008, 13, 944-951.	3.2	131
49	Recent Developments in Fragment-Based Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3661-3680.	2.9	570
50	Fragment-Based Drug Discovery Using Rational Design. Ernst Schering Research Foundation Workshop, 2008, , 169-185.	0.7	16
51	Designing a Fragment Process to Fit Your Needs. , 0, , 15-37.		4
52	New G-protein-coupled receptor crystal structures: insights and limitations. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 79-83.	4.0	217
53	Identification of <i>N</i> -(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1 <i>H</i> -pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4986-4999.	2.9	317
54	Fragment-Based Drug Discovery. , 2008, , 228-243.		5
55	Protein Crystallography and Drug Discovery. , 2008, , 605-634.		3

#	ARTICLE	IF	CITATIONS
56	Fragment-Based Approach to Drug Lead Discovery. <i>Drugs in R and D</i> , 2008, 9, 217-227.	1.1	51
57	Hunting for predictive computational drug-discovery models. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 291-293.	2.0	1
58	Geometrical Preferences of the Hydrogen Bonds on Protein-Ligand Binding Interface Derived from Statistical Surveys and Quantum Mechanics Calculations. <i>Journal of Chemical Theory and Computation</i> , 2008, 4, 1959-1973.	2.3	27
59	Multiple and Single Binding Modes of Fragment-Like Kinase Inhibitors Revealed by Molecular Modeling, Residue Type-Selective Protonation, and Nuclear Overhauser Effects. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6225-6229.	2.9	13
60	Novel Prostaglandin D Synthase Inhibitors Generated by Fragment-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2178-2186.	2.9	61
61	Ligand-Target Interaction-Based Weighting of Substructures for Virtual Screening. <i>Journal of Chemical Information and Modeling</i> , 2008, 48, 1955-1964.	2.5	33
62	Modern cancer drug discovery: integrating targets, technologies and treatments. , 2008, , 3-38.		4
63	DNA-Encoded Chemical Libraries for the Discovery of MMP-3 Inhibitors. <i>Bioconjugate Chemistry</i> , 2008, 19, 778-785.	1.8	86
64	Function-Biased Choice of Additives for Optimization of Protein Crystallization: The Case of the Putative Thioesterase PA5185 from <i>Pseudomonas aeruginosa</i> PAO1. <i>Crystal Growth and Design</i> , 2008, 8, 4054-4061.	1.4	5
65	Binding Synergy and Cooperativity in Dihydrodipicolinate Reductase: Implications for Mechanism and the Design of Bifunctional Inhibitors. <i>Biochemistry</i> , 2008, 47, 9966-9980.	1.2	8
66	Label-Free Primary Screening and Affinity Ranking of Fragment Libraries Using Parallel Analysis of Protein Panels. <i>Journal of Biomolecular Screening</i> , 2008, 13, 202-209.	2.6	50
67	Compound Properties and Drug Quality. , 2008, , 481-490.		4
68	Membrane Transporters: Structure, Function and Targets for Drug Design. <i>Topics in Medicinal Chemistry</i> , 2008, , 15-51.	0.4	5
69	Virtual Screening and Its Integration with Modern Drug Design Technologies. <i>Current Medicinal Chemistry</i> , 2008, 15, 37-46.	1.2	189
70	Virtual Screening of Drugs: Score Functions, Docking, and Drug Design. <i>Current Computer-Aided Drug Design</i> , 2008, 4, 265-272.	0.8	36
71	Molecular Recognition of Ligands by Native Viruses and Virus-Like Particles as Studied by NMR Experiments. <i>Topics in Current Chemistry</i> , 2008, 273, 183-202.	4.0	18
73	Assembling a Fragment Library. , 0, , 39-62.		6
74	Identification of High-Affinity Secretase Inhibitors Using Fragment-Based Lead Generation. , 0, , 261-279.		3

#	ARTICLE	IF	CITATIONS
75	Virtual Fragment Scanning: Current Trends, Applications and Web-Based Tools. , 0, , 223-244.		1
76	Target-Immobilized NMR Screening: Validation and Extension to Membrane Proteins. , 0, , 135-157.		1
80	Computer applications for prediction of protein&ndash;protein interactions and rational drug design. Advances and Applications in Bioinformatics and Chemistry, 2009, , 101.	1.6	3
81	NMR Spectroscopy in Fragment Based Drug Design. Topics in Medicinal Chemistry, 2009, , 125-139.	0.4	1
82	What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 304-315.	1.3	47
83	Drug discovery and the medicinal chemist. Future Medicinal Chemistry, 2009, 1, 11-15.	1.1	5
84	Structural and Computational Biology of the Molecular Chaperone Hsp90: From Understanding Molecular Mechanisms to Computer-Based Inhibitor Design. Current Topics in Medicinal Chemistry, 2009, 9, 1369-1385.	1.0	24
85	Fragment-Based Cocktail Crystallography by the Medical Structural Genomics of Pathogenic Protozoa Consortium. Current Topics in Medicinal Chemistry, 2009, 9, 1678-1687.	1.0	36
86	A Multi-Step NMR Screen for the Identification and Evaluation of Chemical Leads for Drug Discovery. Combinatorial Chemistry and High Throughput Screening, 2009, 12, 285-295.	0.6	21
87	Hit Triage: Medicinal Chemistry Strategies to Improve the Odds of Success in Discovery. Topics in Medicinal Chemistry, 2009, , 141-174.	0.4	1
88	Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 262-267.	3.3	134
89	Structure-based design of molecular cancer therapeutics. Trends in Biotechnology, 2009, 27, 315-328.	4.9	64
90	Dynamic template-assisted strategies in fragment-based drug discovery. Trends in Biotechnology, 2009, 27, 512-521.	4.9	45
91	Two "Golden Ratio"™ indices in fragment-based drug discovery. Drug Discovery Today, 2009, 14, 321-328.	3.2	54
92	Ligand efficiency and fragment-based drug discovery. Drug Discovery Today, 2009, 14, 278-283.	3.2	173
93	From fragment to clinical candidate—a historical perspective. Drug Discovery Today, 2009, 14, 668-675.	3.2	200
94	Picking up the pieces with FBDD or FADD: invest early for future success. Drug Discovery Today, 2009, 14, 623-624.	3.2	15
95	NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discovery Today, 2009, 14, 1051-1057.	3.2	150

#	ARTICLE	IF	CITATIONS
96	The chemist as astronaut: Searching for biologically useful space in the chemical universe. <i>Biochemical Pharmacology</i> , 2009, 78, 217-223.	2.0	40
97	Development of Small-Molecule Ligands and Inhibitors. , 0, , 115-147.		0
98	Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. <i>Annals of Neurology</i> , 2009, 65, 209-217.	2.8	78
100	Rendezvous im Magnetfeld. NMR-Spektren bei der Wirkstoffsuche. <i>Chemie in Unserer Zeit</i> , 2009, 43, 348-357.	0.1	0
101	Design of tRNA <sup>Lys</sup> 3 Ligands: Fragment Evolution and Linker Selection Guided by NMR Spectroscopy. <i>Chemistry - A European Journal</i> , 2009, 15, 7109-7116.	1.7	20
102	On-Chip Fragment-Based Approach for Discovery of High-Affinity Bivalent Inhibitors. <i>ChemBioChem</i> , 2009, 10, 838-843.	1.3	10
103	Library screening by fragment-based docking. <i>Journal of Molecular Recognition</i> , 2010, 23, 183-193.	1.1	32
104	NMR metabolomics and drug discovery. <i>Magnetic Resonance in Chemistry</i> , 2009, 47, S2-11.	1.1	92
107	Covalent Capture: Merging Covalent and Noncovalent Synthesis. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 2288-2306.	7.2	84
108	Selective Identification of Cooperatively Binding Fragments in a High-Throughput Ligation Assay Enables Development of a Picomolar Caspase-3 Inhibitor. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 6346-6349.	7.2	45
109	Application of Fragment Growing and Fragment Linking to the Discovery of Inhibitors of <i>Mycobacterium tuberculosis</i> Pantothenate Synthetase. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 8452-8456.	7.2	138
110	Design of compound libraries for fragment screening. <i>Journal of Computer-Aided Molecular Design</i> , 2009, 23, 513-525.	1.3	69
111	Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. <i>Journal of Computer-Aided Molecular Design</i> , 2009, 23, 541-554.	1.3	147
112	Lessons for fragment library design: analysis of output from multiple screening campaigns. <i>Journal of Computer-Aided Molecular Design</i> , 2009, 23, 603-620.	1.3	113
113	The multiple roles of computational chemistry in fragment-based drug design. <i>Journal of Computer-Aided Molecular Design</i> , 2009, 23, 459-473.	1.3	46
114	Fragment-based drug discovery. <i>Journal of Computer-Aided Molecular Design</i> , 2009, 23, 453-458.	1.3	37
115	Combinatorial library-based design with Basis Products. <i>Journal of Computer-Aided Molecular Design</i> , 2009, 23, 725-736.	1.3	12
116	Emergent strategies for inverse molecular design. <i>Science in China Series B: Chemistry</i> , 2009, 52, 1769-1776.	0.8	9

#	ARTICLE	IF	CITATIONS
117	Direct optical detection in fragment-based screening. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 393, 1557-1562.	1.9	29
118	The rise of fragment-based drug discovery. <i>Nature Chemistry</i> , 2009, 1, 187-192.	6.6	626
119	Bioactivity-guided mapping and navigation of chemical space. <i>Nature Chemical Biology</i> , 2009, 5, 585-592.	3.9	129
120	Fragment-based drug discovery takes a virtual turn. <i>Nature Chemical Biology</i> , 2009, 5, 274-275.	3.9	21
121	Traceless native protein labeling in mice. <i>Nature Chemical Biology</i> , 2009, 5, 275-276.	3.9	3
123	Identification of Allosteric PIF Pocket Ligands for PDK1 using NMR-Based Fragment Screening and <sup>15</sup> N TROSY Experiments. <i>Chemical Biology and Drug Design</i> , 2009, 73, 179-188.	1.5	55
124	Analysis of Flavonoid-Based Pharmacophores that Inhibit Aggrecanases (ADAMTS <sup>4</sup> and ADAMTS <sup>5</sup> ) and Matrix Metalloproteinases Through the Use of Topologically Constrained Peptide Substrates. <i>Chemical Biology and Drug Design</i> , 2009, 74, 473-482.	1.5	13
125	Molecular docking: theoretical background, practical applications and perspectives. <i>Mendeleev Communications</i> , 2009, 19, 237-242.	0.6	22
126	Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1. <i>Journal of Molecular Graphics and Modelling</i> , 2009, 28, 203-219.	1.3	19
127	Mastering the Chemical Language of Bacteria. <i>Chemistry and Biology</i> , 2009, 16, 913-914.	6.2	5
128	Discovery of TNF Inhibitors from a DNA-Encoded Chemical Library based on Diels-Alder Cycloaddition. <i>Chemistry and Biology</i> , 2009, 16, 1075-1086.	6.2	109
129	Discovery of Highly Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase by Fragment Hopping. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 779-797.	2.9	86
130	Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 379-388.	2.9	304
131	QSAR analysis and molecular modeling of ABCG2-specific inhibitors. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 34-46.	6.6	68
132	Structure-based Ligand Design and the Promise Held for Antiprotozoan Drug Discovery. <i>Journal of Biological Chemistry</i> , 2009, 284, 11749-11753.	1.6	43
133	Steering Protein-Ligand Docking with Quantitative NMR Chemical Shift Perturbations. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 2260-2271.	2.5	37
134	A Basis for Reduced Chemical Library Inhibition of Firefly Luciferase Obtained from Directed Evolution. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1450-1458.	2.9	70
135	Streamlining hit discovery and optimization with a yoctoliter scale DNA reactor. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 1201-1213.	2.5	12



#	ARTICLE	IF	CITATIONS
136	Beyond the Virtual Screening Paradigm: Structure-Based Searching for New Lead Compounds. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 800-809.	2.5	31
137	Ligand Mapping on Protein Surfaces by the 3D-RISM Theory: Toward Computational Fragment-Based Drug Design. <i>Journal of the American Chemical Society</i> , 2009, 131, 12430-12440.	6.6	109
138	Recent progress in fragment-based lead discovery. <i>Current Opinion in Pharmacology</i> , 2009, 9, 615-621.	1.7	129
139	Novel trends in high-throughput screening. <i>Current Opinion in Pharmacology</i> , 2009, 9, 580-588.	1.7	550
140	Design and NMR-Based Screening of LEF, a Library of Chemical Fragments with Different Local Environment of Fluorine. <i>Journal of the American Chemical Society</i> , 2009, 131, 12949-12959.	6.6	112
141	QM/MM As a Tool in Fragment Based Drug Discovery. A Cross-Docking, Rescoring Study of Kinase Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 1437-1448.	2.5	46
142	Small-World Phenomena in Chemical Library Networks: Application to Fragment-Based Drug Discovery. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 2677-2686.	2.5	26
143	Computational Fragment-Based Approach at PDB Scale by Protein Local Similarity. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 280-294.	2.5	42
144	Overview of computational methods employed in early-stage drug discovery. <i>Future Medicinal Chemistry</i> , 2009, 1, 49-63.	1.1	10
145	Medicinal Chemistry by the Numbers: The Physicochemistry, Thermodynamics and Kinetics of Modern Drug Design. <i>Progress in Medicinal Chemistry</i> , 2009, 48, 1-29.	4.1	36
146	Discovery of Antibacterial Biotin Carboxylase Inhibitors by Virtual Screening and Fragment-Based Approaches. <i>ACS Chemical Biology</i> , 2009, 4, 473-483.	1.6	84
147	Fragment-Based Drug Discovery in Academia: Experiences From a Tuberculosis Programme. <i>NATO Science for Peace and Security Series A: Chemistry and Biology</i> , 2009, , 21-36.	0.5	4
148	Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3- <i>d</i> ]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4794-4809.	2.9	157
149	Lead Discovery Using Virtual Screening. <i>Topics in Medicinal Chemistry</i> , 2009, , 85-124.	0.4	0
150	Fragment-Based Drug Discovery of Kinase Inhibitors. , 0, , 461-483.		16
151	One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4454-4465.	2.9	96
152	Compounds Binding to the S2â <sup>â</sup> S3 Pockets of Thrombin. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2708-2715.	2.9	31
153	In Silico Fragment Screening by Replica Generation (FSRG) Method for Fragment-Based Drug Design. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 925-933.	2.5	18

#	ARTICLE	IF	CITATIONS
154	High-throughput and <i>in silico</i> screenings in drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 947-959.	2.5	75
155	Advances in fragment-based drug discovery platforms. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 1125-1144.	2.5	28
156	Advances in nuclear magnetic resonance for drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 1077-1098.	2.5	42
157	Emerging cognitive enhancing drugs. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 577-589.	1.0	14
158	Design and Implementation of an Ribonucleic Acid (RNA) Directed Fragment Library. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3753-3761.	2.9	33
159	Start Small and Stay Small: Minimizing Attrition in the Clinic with a Focus on CNS Therapeutics. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1688-1704.	1.0	6
160	Target Immobilization and NMR Screening of Fragments in Early Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1736-1745.	1.0	15
161	Hit Triage Using Efficiency Indices after Screening of Compound Libraries in Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1718-1724.	1.0	14
162	The Seattle Structural Genomics Center for Infectious Disease (SSGCID). <i>Infectious Disorders - Drug Targets</i> , 2009, 9, 493-506.	0.4	88
168	Computational methods and software in computer-aided combinatorial library design. <i>Russian Journal of General Chemistry</i> , 2010, 80, 2541-2571.	0.3	1
169	Methods for Combinatorial and Parallel Library Design. <i>Methods in Molecular Biology</i> , 2010, 672, 387-434.	0.4	7
170	Some Trends in Chem(o)informatics. <i>Methods in Molecular Biology</i> , 2010, 672, 1-37.	0.4	18
171	Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. <i>Nature Communications</i> , 2010, 1, 80.	5.8	675
172	Two-Step Synthesis of Aza- and Diazaindoles from Chloroamino-N-heterocycles Using Ethoxyvinylborolane. <i>Journal of Organic Chemistry</i> , 2010, 75, 11-15.	1.7	62
173	Structural biology in fragment-based drug design. <i>Current Opinion in Structural Biology</i> , 2010, 20, 497-507.	2.6	190
174	Troubleshooting computational methods in drug discovery. <i>Journal of Pharmacological and Toxicological Methods</i> , 2010, 61, 67-75.	0.3	43
175	Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. <i>Drug Discovery Today</i> , 2010, 15, 804-811.	3.2	102
176	Scaffold Distributions in Bioactive Molecules, Clinical Trials Compounds, and Drugs. <i>ChemMedChem</i> , 2010, 5, 187-190.	1.6	22

#	ARTICLE	IF	CITATIONS
177	Fragment-Based Lead Discovery: Screening and Optimizing Fragments for Thermolysin Inhibition. <i>ChemMedChem</i> , 2010, 5, 930-940.	1.6	22
178	Discovery of a Novel Hsp90 Inhibitor by Fragment Linking. <i>ChemMedChem</i> , 2010, 5, 1697-1700.	1.6	48
179	Multiple ligand simultaneous docking: Orchestrated dancing of ligands in binding sites of protein. <i>Journal of Computational Chemistry</i> , 2010, 31, 2014-2022.	1.5	42
180	The Advantage of Covalent Capture in the Combinatorial Screening of a Dynamic Library for the Detection of Weak Interactions. <i>European Journal of Organic Chemistry</i> , 2010, 2010, 3858-3866.	1.2	8
182	Towards Dynamic Drug Design: Identification and Optimization of Galactosidase Inhibitors from a Dynamic Hemithioacetal System. <i>ChemBioChem</i> , 2010, 11, 1600-1606.	1.3	27
184	A Fragment-Based In-Situ Combinatorial Approach To Identify High-Affinity Ligands for Unknown Binding Sites. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 5721-5725.	7.2	46
185	Aroma WaterLOGSY: a fast and sensitive screening tool for drug discovery. <i>Magnetic Resonance in Chemistry</i> , 2010, 48, 909-911.	1.1	17
186	Screening the bioactive compounds in aqueous extract of <i>Coptidis rhizoma</i> which specifically bind to rabbit lung tissues $\beta$ 2-adrenoceptor using an affinity chromatographic selection method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2029-2034.	1.2	24
187	Synergistic effects in the designs of neuraminidase ligands: Analysis from docking and molecular dynamics studies. <i>Journal of Theoretical Biology</i> , 2010, 267, 363-374.	0.8	23
188	Regioselective addition reactions at C-2 of 3,4-dihydropyrimidinones. Synthesis and evaluation of multifunctionalized tetrahydropyrimidines. <i>Tetrahedron</i> , 2010, 66, 8175-8180.	1.0	13
189	Synthesis of bridged 1,4-diazepane derivatives via Schmidt reactions. <i>Tetrahedron Letters</i> , 2010, 51, 1790-1792.	0.7	5
190	A fluorescence correlation spectroscopy-based assay for fragment screening of slowly inhibiting protein-peptide interaction inhibitors. <i>Analytical Biochemistry</i> , 2010, 402, 26-31.	1.1	14
191	Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant. <i>Chemistry and Biology</i> , 2010, 17, 46-56.	6.2	97
192	Application of Fragment-Based Drug Discovery to Membrane Proteins: Identification of Ligands of the Integral Membrane Enzyme DsbB. <i>Chemistry and Biology</i> , 2010, 17, 881-891.	6.2	70
193	Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5056-5062.	1.4	26
194	Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1821-1824.	1.0	25
195	Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2552-2555.	1.0	15
196	In-crystal chemical ligation for lead compound generation. <i>Journal of Applied Crystallography</i> , 2010, 43, 1329-1337.	1.9	8

#	ARTICLE	IF	CITATIONS
197	Fragment-Based Screen against HIV Protease. <i>Chemical Biology and Drug Design</i> , 2010, 75, 257-268.	1.5	61
198	Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. <i>Nature Chemical Biology</i> , 2010, 6, 660-666.	3.9	110
199	The antibacterial lead discovery challenge. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 751-752.	21.5	32
204	Novel anti-tuberculosis drug designs by data mining for similarity in substituent substitution and structure modification. <i>Drugs and Therapy Studies</i> , 2010, 1, 15.	0.6	1
206	Thermodynamic Additivity of Sequence Variations: An Algorithm for Creating High Affinity Peptides Without Large Libraries or Structural Information. <i>PLoS ONE</i> , 2010, 5, e15432.	1.1	12
207	NMR in fragment-based drug discovery. , 2010, , 41-58.		2
208	An efficient and information-rich biochemical method design for fragment library screening on ion channels. <i>BioTechniques</i> , 2010, 49, 822-829.	0.8	16
209	Fragment-Based Screening by Biochemical Assays: Systematic Feasibility Studies with Trypsin and MMP12. <i>Journal of Biomolecular Screening</i> , 2010, 15, 1029-1041.	2.6	37
210	Native MS: an <sup>1</sup> H-MS way to support structure- and fragment-based drug discovery. <i>Future Medicinal Chemistry</i> , 2010, 2, 35-50.	1.1	82
211	When analoging is not enough: scaffold discovery in medicinal chemistry. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 123-134.	2.5	20
212	Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors. <i>Biochemical Journal</i> , 2010, 431, 51-61.	1.7	41
214	SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moieties. <i>Nucleic Acids Research</i> , 2010, 38, W424-W430.	6.5	37
215	Strategies for the design of RNA-binding small molecules. <i>Future Medicinal Chemistry</i> , 2010, 2, 93-119.	1.1	72
216	Contributions of Computational Chemistry and Biophysical Techniques to Fragment-Based Drug Discovery. <i>Current Medicinal Chemistry</i> , 2010, 17, 1769-1794.	1.2	38
217	Computational Approaches for Fragment-Based and De Novo Design. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 14-32.	1.0	100
218	Understanding Functional Residues of the Cannabinoid CB1 Receptor for Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 779-798.	1.0	34
219	Novel Therapies in Childhood Heart Failure: Today and Tomorrow. <i>Heart Failure Clinics</i> , 2010, 6, 591-621.	1.0	8
220	Theoretical and Computational Approaches to Biomolecular Structure. <i>Interdisciplinary Applied Mathematics</i> , 2010, , 237-264.	0.2	0

#	ARTICLE	IF	CITATIONS
221	Force Fields. <i>Interdisciplinary Applied Mathematics</i> , 2010, , 265-298.	0.2	0
222	Application of Fragment-Based NMR Screening, X-ray Crystallography, Structure-Based Design, and Focused Chemical Library Design to Identify Novel $\beta$ -Site APP Tj ETQ 1 1 0.784314 nF	1.0	14
223	Fragment-based QSAR strategies in drug design. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 405-412.	2.5	17
224	Ligand Specificity in Fragment-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5256-5266.	2.9	50
225	Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1172-1189.	2.9	146
226	Ligand efficiency as a guide in fragment hit selection and optimization. <i>Drug Discovery Today: Technologies</i> , 2010, 7, e157-e162.	4.0	167
227	Fragments: past, present and future. <i>Drug Discovery Today: Technologies</i> , 2010, 7, e163-e171.	4.0	39
228	Matrix Metalloproteinase Inhibitors. <i>Drugs</i> , 2010, 70, 949-964.	4.9	163
229	Drug Discovery with DNA-Encoded Chemical Libraries. <i>Bioconjugate Chemistry</i> , 2010, 21, 1571-1580.	1.8	52
230	Electron Density Guided Fragment-Based Lead Discovery of Ketohexokinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7979-7991.	2.9	33
231	Identification and Characterization of Acidic Mammalian Chitinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6122-6128.	2.9	38
233	Chemical Fragments that Hydrogen Bond to Asp, Glu, Arg, and His Side Chains in Protein Binding Sites. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3086-3094.	2.9	33
234	Novel sinomenine derivative 1032 improves immune suppression in experimental autoimmune encephalomyelitis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 1093-1098.	1.0	21
235	Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5942-5955.	2.9	173
236	Fragment-Based Deconstruction of Bcl-x <sub>L</sub> Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2577-2588.	2.9	62
237	Novel Small Molecule Inhibitors of MDR <i>Mycobacterium tuberculosis</i> by NMR Fragment Screening of Antigen 85C. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8362-8367.	2.9	32
238	<i>In silico</i> fragment-based drug design. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 1047-1065.	2.5	24
239	Design of a High Fragment Efficiency Library by Molecular Graph Theory. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 499-503.	1.3	14

#	ARTICLE	IF	CITATIONS
241	Modular architecture of nucleotide-binding pockets. <i>Nucleic Acids Research</i> , 2010, 38, 3809-3816.	6.5	24
242	Electrokinetic label-free screening chip: a marriage of multiplexing and high throughput analysis using surface plasmon resonance imaging. <i>Lab on A Chip</i> , 2010, 10, 986.	3.1	32
243	Interactive Drug Design in Virtual Reality. , 2011, , .		5
244	Design and Evaluation of Fragment-Like Estrogen Receptor Tetrahydroisoquinoline Ligands from a Scaffold-Detection Approach. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2005-2011.	2.9	12
245	20 years of DNA-encoded chemical libraries. <i>Chemical Communications</i> , 2011, 47, 12747.	2.2	124
246	DNA-templated combinatorial assembly of small molecule fragments amenable to selection/amplification cycles. <i>Chemical Science</i> , 2011, 2, 625.	3.7	75
247	Fragment screening against the thiamine pyrophosphate riboswitchthiM. <i>Chemical Science</i> , 2011, 2, 157-165.	3.7	46
248	A general synthesis of dirhodium metallopeptides as MDM2 ligands. <i>Chemical Communications</i> , 2011, 47, 10927.	2.2	24
249	Conserved Core Substructures in the Overlay of Proteinâ€“Ligand Complexes. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 1931-1941.	2.5	13
250	Broad Distribution of Energetically Important Contacts across an Extended Protein Interface. <i>Journal of the American Chemical Society</i> , 2011, 133, 10038-10041.	6.6	39
251	Residue Preference Mapping of Ligand Fragments in the Protein Data Bank. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 807-815.	2.5	20
252	Structure of the HIV-1 Frameshift Site RNA Bound to a Small Molecule Inhibitor of Viral Replication. <i>ACS Chemical Biology</i> , 2011, 6, 857-864.	1.6	55
253	Route to three-dimensional fragments using diversity-oriented synthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 6799-6804.	3.3	246
254	Structure-Based Fragment Hopping for Lead Optimization Using Predocked Fragment Database. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 1703-1715.	2.5	12
255	Fragment Screening Using X-Ray Crystallography. <i>Topics in Current Chemistry</i> , 2011, 317, 33-59.	4.0	65
256	Combining Biophysical Screening and X-Ray Crystallography for Fragment-Based Drug Discovery. <i>Topics in Current Chemistry</i> , 2011, 317, 115-143.	4.0	40
257	Computational Approach to De Novo Discovery of Fragment Binding for Novel Protein States. <i>Methods in Enzymology</i> , 2011, 493, 357-380.	0.4	2
258	Electron Density Guided Fragment-Based Drug Designâ€“A Lead Generation Example. <i>Methods in Enzymology</i> , 2011, 493, 487-508.	0.4	6

#	ARTICLE	IF	CITATIONS
259	Assessing Helical Protein Interfaces for Inhibitor Design. <i>Journal of the American Chemical Society</i> , 2011, 133, 14220-14223.	6.6	261
261	Fragment Growing Induces Conformational Changes in Acetylcholine-Binding Protein: A Structural and Thermodynamic Analysis. <i>Journal of the American Chemical Society</i> , 2011, 133, 5363-5371.	6.6	72
263	Practical Aspects of NMR-Based Fragment Screening. <i>Methods in Enzymology</i> , 2011, 493, 219-239.	0.4	53
264	New era for drug discovery and development in renal disease. <i>Nature Reviews Nephrology</i> , 2011, 7, 469-477.	4.1	17
265	Key Factors for Successful Generation of Protein-Fragment Structures. <i>Methods in Enzymology</i> , 2011, 493, 61-89.	0.4	16
266	Predicting the Success of Fragment Screening by X-Ray Crystallography. <i>Methods in Enzymology</i> , 2011, 493, 91-114.	0.4	10
267	Fragment Screening Purely with Protein Crystallography. <i>Methods in Enzymology</i> , 2011, 493, 321-356.	0.4	20
268	Predicting Fragment Binding Poses Using a Combined MCSS MM-GBSA Approach. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 1092-1105.	2.5	43
269	Cheminformatics and Computational Chemical Biology. <i>Methods in Molecular Biology</i> , 2011, , .	0.4	10
270	Rational Methods for the Selection of Diverse Screening Compounds. <i>ACS Chemical Biology</i> , 2011, 6, 208-217.	1.6	98
271	Ligand discovery from a dopamine D3 receptor homology model and crystal structure. <i>Nature Chemical Biology</i> , 2011, 7, 769-778.	3.9	285
272	Design of Screening Collections for Successful Fragment-Based Lead Discovery. <i>Methods in Molecular Biology</i> , 2011, 685, 219-240.	0.4	4
273	Introduction to Fragment-Based Drug Discovery. <i>Topics in Current Chemistry</i> , 2011, 317, 1-32.	4.0	178
274	Computational medicinal chemistry in fragment-based drug discovery: what, how and when. <i>Future Medicinal Chemistry</i> , 2011, 3, 95-134.	1.1	17
275	Combining NMR and X-ray Crystallography in Fragment-Based Drug Discovery: Discovery of Highly Potent and Selective BACE-1 Inhibitors. <i>Topics in Current Chemistry</i> , 2011, 317, 83-114.	4.0	49
276	X-ray crystallography: assessment and validation of protein-small molecule complexes for drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 771-782.	2.5	53
277	Fragment-Based Approaches and Computer-Aided Drug Discovery. <i>Topics in Current Chemistry</i> , 2011, 317, 201-222.	4.0	31
278	Emerging role of surface plasmon resonance in fragment-based drug discovery. <i>Future Medicinal Chemistry</i> , 2011, 3, 1809-1820.	1.1	53

#	ARTICLE	IF	CITATIONS
279	Identification of a Novel Scaffold for Allosteric Inhibition of Wild Type and Drug Resistant HIV-1 Reverse Transcriptase by Fragment Library Screening. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 699-708.	2.9	41
280	Hsp90 Inhibitors and Drugs from Fragment and Virtual Screening. <i>Topics in Current Chemistry</i> , 2011, 317, 61-82.	4.0	29
281	A Small-Molecule Probe Induces a Conformation in HIV TAR RNA Capable of Binding Drug-Like Fragments. <i>Journal of Molecular Biology</i> , 2011, 410, 984-996.	2.0	50
282	The Retinal Specific CD147 IgO Domain: From Molecular Structure to Biological Activity. <i>Journal of Molecular Biology</i> , 2011, 411, 68-82.	2.0	27
283	Correlation between Protein Function and Ligand Binding Profiles. <i>Journal of Proteome Research</i> , 2011, 10, 2538-2545.	1.8	12
284	Binding Site Identification and Structure Determination of Protein-Ligand Complexes by NMR. <i>Methods in Enzymology</i> , 2011, 493, 241-275.	0.4	58
285	Novel Strategy for Three-Dimensional Fragment-Based Lead Discovery. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 959-974.	2.5	20
286	Fragment-Based Ligand Discovery. , 0, , 74-86.		0
288	Chemical Properties of Air Pollutants and Cause-Specific Hospital Admissions among the Elderly in Atlanta, Georgia. <i>Environmental Health Perspectives</i> , 2011, 119, 1421-1428.	2.8	57
289	P-glycoprotein Inhibition: The Past, the Present and the Future. <i>Current Drug Metabolism</i> , 2011, 12, 722-731.	0.7	80
290	Modern Drug Discovery Technologies: Opportunities and Challenges in Lead Discovery. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2011, 14, 830-839.	0.6	37
291	Discovery of Modulators of Protein-Protein Interactions: Current Approaches and Limitations. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 248-257.	1.0	66
292	Antibody fragments as tools in crystallography. <i>Clinical and Experimental Immunology</i> , 2011, 165, 285-291.	1.1	55
293	Targeting Metalloproteins by Fragment-Based Lead Discovery. <i>Chemical Biology and Drug Design</i> , 2011, 78, 211-223.	1.5	15
294	A question of library design. <i>Nature</i> , 2011, 470, 42-43.	13.7	104
295	Phenome-transcriptome correlation unravels anxiety and depression related pathways. <i>Journal of Psychiatric Research</i> , 2011, 45, 973-979.	1.5	57
296	A molecular informatics view on best practice in multi-parameter compound optimization. <i>Drug Discovery Today</i> , 2011, 16, 555-568.	3.2	19
297	Fragment-Based Drug Discovery for Diseases of the Central Nervous System. <i>ACS Symposium Series</i> , 2011, , 179-192.	0.5	0



#	ARTICLE	IF	CITATIONS
298	Design and Application of Fragment Libraries for Protein Crystallography. ACS Symposium Series, 2011, , 45-56.	0.5	0
299	Lessons Learned from Molecular Scaffold Analysis. Journal of Chemical Information and Modeling, 2011, 51, 1742-1753.	2.5	82
300	A Strategy for Neuraminidase Inhibitors Using Mechanism-Based Labeling Information. Chemistry - an Asian Journal, 2011, 6, 1048-1056.	1.7	10
301	Visualisation and subsets of the chemical universe database GDB-13 for virtual screening. Journal of Computer-Aided Molecular Design, 2011, 25, 637-647.	1.3	44
302	Visualisation of the chemical space of fragments, lead-like and drug-like molecules in PubChem. Journal of Computer-Aided Molecular Design, 2011, 25, 649-662.	1.3	26
303	Biosensor-based small molecule fragment screening with biolayer interferometry. Journal of Computer-Aided Molecular Design, 2011, 25, 669-676.	1.3	110
304	Fragment-based lead discovery: challenges and opportunities. Journal of Computer-Aided Molecular Design, 2011, 25, 607-610.	1.3	22
305	Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery. Journal of Computer-Aided Molecular Design, 2011, 25, 689-698.	1.3	16
306	Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei. Journal of Structural and Functional Genomics, 2011, 12, 63-76.	1.2	19
307	Screening a fragment cocktail library using ultrafiltration. Analytical and Bioanalytical Chemistry, 2011, 401, 1585-1591.	1.9	9
308	In-crystal affinity ranking of fragment hit compounds reveals a relationship with their inhibitory activities. Journal of Applied Crystallography, 2011, 44, 798-804.	1.9	21
309	Ligand Efficiency Indices (LEIs): More than a Simple Efficiency Yardstick. Molecular Informatics, 2011, 30, 122-132.	1.4	21
310	Compound Design by Fragment-Linking. Molecular Informatics, 2011, 30, 298-306.	1.4	82
311	Rapid acquisition of <sup>1</sup> H and <sup>19</sup> F NMR experiments for direct and competition ligand-based screening. Magnetic Resonance in Chemistry, 2011, 49, 199-202.	1.1	19
312	One-Pot Regioselective Double-Mannich Annulations Affording Azabicyclononanones as a Key Step in the Synthesis of Natural Products. European Journal of Organic Chemistry, 2011, 2011, 5336-5346.	1.2	10
313	Fragment-Based Design of Ligands Targeting a Novel Site on the Integrase Enzyme of Human Immunodeficiency Virus-1. ChemMedChem, 2011, 6, 258-261.	1.6	24
314	Complementary Screening Techniques Yielded Fragments that Inhibit the Phosphatase Activity of Soluble Epoxide Hydrolase. ChemMedChem, 2011, 6, 2146-2149.	1.6	13
316	Heteroditopic Binding of Magnetic Resonance Contrast Agents for Increased Relaxivity. Angewandte Chemie - International Edition, 2011, 50, 2621-2624.	7.2	28

#	ARTICLE	IF	CITATIONS
317	Ligand specificity, privileged substructures and protein druggability from fragment-based screening. <i>Current Opinion in Chemical Biology</i> , 2011, 15, 469-474.	2.8	48
318	Molecular complexity and fragment-based drug discovery: ten years on. <i>Current Opinion in Chemical Biology</i> , 2011, 15, 489-496.	2.8	152
319	Efficiency of hit generation and structural characterization in fragment-based ligand discovery. <i>Current Opinion in Chemical Biology</i> , 2011, 15, 482-488.	2.8	34
320	Unexpected stereochemical tolerance for the biological activity of tyroscherin. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1708-1713.	1.4	4
321	X-ray and molecular modelling in fragment-based design of three small quinoline scaffolds for HIV integrase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1606-1612.	1.4	15
322	Ethyl malonate amides: A diketo acid offspring fragment for HIV integrase inhibition. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 5000-5005.	1.4	9
323	High concentration electrophysiology-based fragment screen: Discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2646-2649.	1.0	19
324	Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3078-3083.	1.0	78
325	New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-Mycobacterium tuberculosis agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3699-3703.	1.0	67
326	Weak affinity chromatography as a new approach for fragment screening in drug discovery. <i>Analytical Biochemistry</i> , 2011, 414, 138-146.	1.1	69
327	An inexpensive high-throughput nuclear magnetic resonance tube cleaning apparatus. <i>Analytical Biochemistry</i> , 2011, 416, 234-236.	1.1	2
328	Rhodium(II) carbene-mediated modification of 2-deoxystreptamine surrogates. <i>Tetrahedron Letters</i> , 2011, 52, 3201-3203.	0.7	15
329	The benefits of constructing leads from fragment hits. <i>Future Medicinal Chemistry</i> , 2011, 3, 1111-1115.	1.1	25
330	From Chemical Graphs in Computer-Aided Drug Design to General Markov-Galvez Indices of Drug-Target, Proteome, Drug-Parasitic Disease, Technological, and Social-Legal Networks. <i>Current Computer-Aided Drug Design</i> , 2011, 7, 315-337.	0.8	10
331	NMR Screening and Hit Validation in Fragment Based Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 43-67.	1.0	50
332	Pairwise additivity of energy components in protein-ligand binding: The HIV II protease-Indinavir case. <i>Journal of Chemical Physics</i> , 2011, 135, 085101.	1.2	19
333	Fragment Screening and HIV Therapeutics. <i>Topics in Current Chemistry</i> , 2011, 317, 181-200.	4.0	20
334	Experimental Validation of a Fragment Library for Lead Discovery Using SPR Biosensor Technology. <i>Journal of Biomolecular Screening</i> , 2011, 16, 15-25.	2.6	31

#	ARTICLE	IF	CITATIONS
335	Recent trends and observations in the design of high-quality screening collections. <i>Future Medicinal Chemistry</i> , 2011, 3, 751-766.	1.1	55
336	Statistical mechanics theory of molecular recognition and pharmaceutical design. <i>International Reviews in Physical Chemistry</i> , 2011, 30, 445-478.	0.9	3
337	Combining ambiguous chemical shift mapping with structure-based backbone and NOE assignment from 15N-NOESY. , 2011, , .		0
338	Phosphate binding sites identification in protein structures. <i>Nucleic Acids Research</i> , 2011, 39, 1231-1242.	6.5	15
339	FragmentStore—a comprehensive database of fragments linking metabolites, toxic molecules and drugs. <i>Nucleic Acids Research</i> , 2011, 39, D1049-D1054.	6.5	19
340	Lessons from the Fersht laboratory could be vital for the future of the pharmaceutical industry. <i>Protein Engineering, Design and Selection</i> , 2011, 24, 65-67.	1.0	0
341	Prediction of Positions of Active Compounds Makes It Possible To Increase Activity in Fragment-Based Drug Development. <i>Pharmaceuticals</i> , 2011, 4, 758-769.	1.7	1
342	The Free Energy Landscape of Small Molecule Unbinding. <i>PLoS Computational Biology</i> , 2011, 7, e1002002.	1.5	93
343	From QSAR models of Drugs to Complex Networks: State-of-Art Review and Introduction of New Markov-Spectral Moments Indices. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 927-960.	1.0	35
344	Drug-Likeness and Increased Hydrophobicity of Commercially Available Compound Libraries for Drug Screening. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 1500-1513.	1.0	47
345	Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. <i>Quarterly Reviews of Biophysics</i> , 2012, 45, 383-426.	2.4	90
346	Modulating Protein-Protein Interactions: From Structural Determinants of Binding to Druggability Prediction to Application. <i>Current Pharmaceutical Design</i> , 2012, 18, 4630-4647.	0.9	54
347	Rapid Protein-Ligand Costructures from Sparse NOE Data. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10786-10790.	2.9	21
348	Fragment and Conquer: From Structure to Complexes to Function. <i>Structure</i> , 2012, 20, 1617-1619.	1.6	2
349	Facial selectivity induced by N-aryl atropisomerism in benzonitrile oxide cycloadditions with 4-methylene-2-oxazolidinones. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 4759.	1.5	12
350	In Silico Deconstruction of ATP-Competitive Inhibitors of Glycogen Synthase Kinase-3 $\beta$ . <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 3233-3244.	2.5	7
351	Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1 $\alpha$ Protein-Protein Interface. <i>Chemistry and Biology</i> , 2012, 19, 1300-1312.	6.2	162
354	Targeting frameshifting in the human immunodeficiency virus. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 249-258.	1.5	49

#	ARTICLE	IF	CITATIONS
355	Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold. <i>Current Medicinal Chemistry</i> , 2012, 19, 1921-1945.	1.2	54
356	An integrated fragment based screening approach for the discovery of small molecule modulators of the VWFâ€“GPIIb/IIIa interaction. <i>Chemical Communications</i> , 2012, 48, 11349.	2.2	11
357	Recent Trends and Applications in 3D Virtual Screening. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2012, 15, 749-769.	0.6	16
358	Identification of Binding Specificity-Determining Features in Protein Families. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1926-1939.	2.9	4
359	Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2474-2478.	2.9	45
360	A Force Field with Discrete Displaceable Waters and Desolvation Entropy for Hydrated Ligand Docking. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 623-638.	2.9	216
361	Profiling the Dynamic Interfaces of Fluorinated Transcription Complexes for Ligand Discovery and Characterization. <i>ACS Chemical Biology</i> , 2012, 7, 1345-1350.	1.6	57
362	Fragment-Based Screening for Inhibitors of PDE4A Using Enthalpy Arrays and X-ray Crystallography. <i>Journal of Biomolecular Screening</i> , 2012, 17, 469-480.	2.6	23
363	Going further than Lipinski's rule in drug design. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 99-107.	2.5	151
364	Fragment Screening of GPCRs Using Biophysical Methods: Identification of Ligands of the Adenosine A <sub>2A</sub> Receptor with Novel Biological Activity. <i>ACS Chemical Biology</i> , 2012, 7, 2064-2073.	1.6	77
365	Fragment-based design of small RNA binders: Promising developments and contribution of NMR. <i>Biochimie</i> , 2012, 94, 1607-1619.	1.3	22
366	From base pair to bedside: molecular simulation and the translation of genomics to personalized medicine. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2012, 4, 585-598.	6.6	11
367	Combining automated peak tracking in SAR by NMR with structure-based backbone assignment from 15N-NOESY. <i>BMC Bioinformatics</i> , 2012, 13, S4.	1.2	15
368	FragVLib a free database mining software for generating "Fragment-based Virtual Library" using pocket similarity search of ligand-receptor complexes. <i>Journal of Cheminformatics</i> , 2012, 4, 18.	2.8	8
370	Selecting, Acquiring, and Using Small Molecule Libraries for Highâ€“Throughput Screening. <i>Current Protocols in Chemical Biology</i> , 2012, 4, 177-191.	1.7	57
371	INPHARMA-based identification of ligand binding site in fragment-based drug design. <i>MedChemComm</i> , 2012, 3, 605.	3.5	16
372	Toward Rational Fragment-Based Lead Design without 3D Structures. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7909-7919.	2.9	11
373	Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 2937-2949.	2.5	36

#	ARTICLE	IF	CITATIONS
374	Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 6770-6789.	1.4	40
375	Therapeutic approaches to preventing cell death in Huntington disease. <i>Progress in Neurobiology</i> , 2012, 99, 262-280.	2.8	24
376	Discovery of small molecule cancer drugs: Successes, challenges and opportunities. <i>Molecular Oncology</i> , 2012, 6, 155-176.	2.1	447
377	Structure-based Design Technology C <sub>ONTOUR</sub> and its Application to Drug Discovery. <i>RSC Biomolecular Sciences</i> , 2012, , 265-280.	0.4	3
378	Protein-Protein Interactions as Drug Targets. <i>Topics in Medicinal Chemistry</i> , 2012, , 1-55.	0.4	5
379	Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces. <i>Topics in Medicinal Chemistry</i> , 2012, , 197-230.	0.4	4
380	Structure- and ligand-based drug design approaches for neglected tropical diseases. <i>Pure and Applied Chemistry</i> , 2012, 84, 1857-1866.	0.9	11
381	Antibody-enabled small-molecule drug discovery. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 519-525.	21.5	63
382	An enthalpic basis of additivity in biphenyl hydroxamic acid ligands for stromelysin-1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6521-6524.	1.0	8
383	Motion planning algorithms for molecular simulations: A survey. <i>Computer Science Review</i> , 2012, 6, 125-143.	10.2	74
384	Hot Spot Analysis for Driving the Development of Hits into Leads in Fragment-Based Drug Discovery. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 199-209.	2.5	52
385	Pharmacophore-based database mining for probing fragmental drug-likeness of diketo acid analogues. <i>SAR and QSAR in Environmental Research</i> , 2012, 23, 185-204.	1.0	10
386	Insulin-Like Growth Factor Binding Proteins: A Structural Perspective. <i>Frontiers in Endocrinology</i> , 2012, 3, 38.	1.5	159
387	Fragment Based Drug Discovery: Practical Implementation Based on <sup>19</sup> F NMR Spectroscopy. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 678-687.	2.9	78
388	Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 576-586.	2.9	182
389	The impact of network biology in pharmacology and toxicology. <i>SAR and QSAR in Environmental Research</i> , 2012, 23, 221-235.	1.0	24
390	Binding Evaluation of Fragment-Based Scaffolds for Probing Allosteric Enzymes. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1287-1295.	2.9	30
391	Aromatic Cations from Oxidative Carbon-Hydrogen Bond Cleavage in Bimolecular Carbon-Carbon Bond Forming Reactions. <i>Journal of Organic Chemistry</i> , 2012, 77, 6574-6582.	1.7	62

#	ARTICLE	IF	CITATIONS
392	Chapter 7. Docking and Virtual Screening. RSC Drug Discovery Series, 2012, , 171-194.	0.2	0
393	<i>In Silico</i> Lead Generation Approaches in Multi-Target Drug Discovery. RSC Drug Discovery Series, 2012, , 130-140.	0.2	2
394	Targeting Protein-Protein Interactions: Dual Inhibitors of Bcl-2 and Bcl-xL. RSC Drug Discovery Series, 2012, , 243-262.	0.2	0
395	Towards the systematic exploration of chemical space. Organic and Biomolecular Chemistry, 2012, 10, 17-28.	1.5	58
396	Strategies and Challenges Involved in the Discovery of New Chemical Entities During Early-Stage Tuberculosis Drug Discovery. Journal of Infectious Diseases, 2012, 205, S258-S264.	1.9	15
397	Conformational Transitions and Convergence of Absolute Binding Free Energy Calculations. Journal of Chemical Theory and Computation, 2012, 8, 47-60.	2.3	60
401	Discovery of Small Molecules that Bind to KRas and Inhibit Sos-Mediated Activation. Angewandte Chemie - International Edition, 2012, 51, 6140-6143.	7.2	419
402	Hybrid Organic-Inorganic Inhibitors of a PDZ Interaction that Regulates the Endocytic Fate of CFTR. Angewandte Chemie - International Edition, 2012, 51, 7217-7220.	7.2	31
403	Discovery of Small-Molecule Interleukin-2 Inhibitors from a DNA-Encoded Chemical Library. Chemistry - A European Journal, 2012, 18, 7729-7737.	1.7	94
404	Experimental and Computational Active Site Mapping as a Starting Point to Fragment-Based Lead Discovery. ChemMedChem, 2012, 7, 248-261.	1.6	31
405	Structure-Based Design of Novel Pyrimido[4,5-c]pyridazine Derivatives as Dihydropteroate Synthase Inhibitors with Increased Affinity. ChemMedChem, 2012, 7, 861-870.	1.6	31
406	Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge. Journal of Computer-Aided Molecular Design, 2012, 26, 603-616.	1.3	15
407	Exhaustive search and solvated interaction energy (SIE) for virtual screening and affinity prediction. Journal of Computer-Aided Molecular Design, 2012, 26, 617-633.	1.3	18
408	A reverse combination of structure-based and ligand-based strategies for virtual screening. Journal of Computer-Aided Molecular Design, 2012, 26, 319-327.	1.3	4
409	Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies. Journal of Molecular Modeling, 2012, 18, 2553-2566.	0.8	7
410	A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A. Analytical Biochemistry, 2012, 421, 742-749.	1.1	39
411	Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability. Chemistry and Biology, 2012, 19, 42-50.	6.2	191
412	Design, synthesis and in vitro evaluation of novel bivalent S-adenosylmethionine analogues. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 278-284.	1.0	9

#	ARTICLE	IF	CITATIONS
413	Screening and In Situ Synthesis Using Crystals of a NAD Kinase Lead to a Potent Antistaphylococcal Compound. <i>Structure</i> , 2012, 20, 1107-1117.	1.6	22
414	Toward a fragment-based approach to MMPs inhibitors: an expedite and efficient synthesis of N-hydroxylactams. <i>Tetrahedron Letters</i> , 2012, 53, 4114-4116.	0.7	8
415	Scientific discovery as a combinatorial optimisation problem: How best to navigate the landscape of possible experiments?. <i>BioEssays</i> , 2012, 34, 236-244.	1.2	44
416	Fragment Deconstruction of Small, Potent Factorâ€¦Xa Inhibitors: Exploring the Superadditivity Energetics of Fragment Linking in Proteinâ€“Ligand Complexes. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 905-911.	7.2	54
417	Fragment Informatics and Computational Fragmentâ€“Based Drug Design: An Overview and Update. <i>Medicinal Research Reviews</i> , 2013, 33, 554-598.	5.0	56
418	Navigating in Chemicobiological Space. , 2013, , 91-105.		0
419	Protein crystallography and fragment-based drug design. <i>Future Medicinal Chemistry</i> , 2013, 5, 1121-1140.	1.1	27
420	Discovery and Biophysical Characterization of 2-Amino-oxadiazoles as Novel Antagonists of PqsR, an Important Regulator of <i>Pseudomonas aeruginosa</i> Virulence. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6761-6774.	2.9	57
421	Bimolecular coupling reactions through oxidatively generated aromatic cations: scope and stereocontrol. <i>Tetrahedron</i> , 2013, 69, 7618-7626.	1.0	43
422	Alzheimerâ€™s Disease: Identification and Development of Î²â€“Secretase (BACEâ€“1) Binding Fragments and Inhibitors by Dynamic Ligation Screening (DLS). <i>ChemMedChem</i> , 2013, 8, 1041-1056.	1.6	14
423	Identification of small-molecule binding pockets in the soluble monomeric form of the AÎ²42 peptide. <i>Journal of Chemical Physics</i> , 2013, 139, 035101.	1.2	72
424	Investigation of the Noncovalent Binding Mode of Covalent Proteasome Inhibitors around the Transition State by Combined Use of Cyclopropylic Strain-Based Conformational Restriction and Computational Modeling. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5829-5842.	2.9	24
425	Screening Technologies for Lead Structure Discovery. , 2013, , 129-152.		0
426	Proteinâ€“protein interactions as druggable targets: recent technological advances. <i>Current Opinion in Pharmacology</i> , 2013, 13, 791-796.	1.7	108
427	Construction of the CSIRO Fragment Library. <i>Australian Journal of Chemistry</i> , 2013, 66, 1473.	0.5	12
428	The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6777-6783.	1.0	29
429	Advanced Technologies for Managing Insect Pests. , 2013, , .		5
433	NMR Study to Identify a Ligand-Binding Pocket in Ras. <i>The Enzymes</i> , 2013, 33 Pt A, 15-39.	0.7	7

#	ARTICLE	IF	CITATIONS
434	Exploring the Chemical Space of Multitarget Ligands Using Aligned Self-Organizing Maps. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1169-1172.	1.3	33
435	Probing structural adaptivity at PPI interfaces with small molecules. <i>Drug Discovery Today: Technologies</i> , 2013, 10, e501-e508.	4.0	21
436	Discovery of a Potent Inhibitor of Replication Protein A Protein-Protein Interactions Using a Fragment-Linking Approach. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9242-9250.	2.9	59
437	Complementarity between in Silico and Biophysical Screening Approaches in Fragment-Based Lead Discovery against the A2A Adenosine Receptor. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 2701-2714.	2.5	65
438	DNA display for drug discovery. <i>RSC Advances</i> , 2013, 3, 16251.	1.7	7
439	Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2013, 60, 410-420.	2.6	24
440	Inhibition of $\alpha$ -helix-mediated protein-protein interactions using designed molecules. <i>Nature Chemistry</i> , 2013, 5, 161-173.	6.6	642
442	Small Targeted Cytotoxics: Current State and Promises from DNA-Encoded Chemical Libraries. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 1384-1402.	7.2	130
444	De novo design - hopping against hope. <i>Drug Discovery Today: Technologies</i> , 2013, 10, e453-e460.	4.0	31
445	Fragment-Based Discovery of 8-Hydroxyquinoline Inhibitors of the HIV-1 Integrase-Lens Epithelium-Derived Growth Factor/p75 (IN-LEDGF/p75) Interaction. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2311-2322.	2.9	55
446	Expanding medicinal chemistry space. <i>Drug Discovery Today</i> , 2013, 18, 298-304.	3.2	78
447	Relay Catalytic Branching Cascade: A Technique to Access Diverse Molecular Scaffolds. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 2251-2255.	7.2	72
448	Techniques, tools and best practices for ligand electron-density analysis and results from their application to deposited crystal structures. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2013, 69, 150-167.	2.5	94
449	Click Chemistry for Drug Development and Diverse Chemical-Biology Applications. <i>Chemical Reviews</i> , 2013, 113, 4905-4979.	23.0	1,534
450	Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. <i>FEBS Journal</i> , 2013, 280, 5957-5980.	2.2	95
452	Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 498-507.	2.6	91
453	Incorporation of Rapid Thermodynamic Data in Fragment-Based Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2155-2159.	2.9	18
454	Small-Molecule Binding Sites on Proteins Established by Paramagnetic NMR Spectroscopy. <i>Journal of the American Chemical Society</i> , 2013, 135, 5859-5868.	6.6	87



#	ARTICLE	IF	CITATIONS
455	Exploiting Specific Interactions toward Next-Generation Polymeric Drug Transporters. <i>Journal of the American Chemical Society</i> , 2013, 135, 1711-1714.	6.6	48
456	Accounting for Conformational Variability in Protein-Ligand Docking with NMR-Guided Rescoring. <i>Journal of the American Chemical Society</i> , 2013, 135, 5819-5827.	6.6	22
457	Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 965-976.	2.5	14
458	Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file. <i>Molecular Diversity</i> , 2013, 17, 319-335.	2.1	7
459	De Novo Design of Protein Kinase Inhibitors by In Silico Identification of Hinge Region-Binding Fragments. <i>ACS Chemical Biology</i> , 2013, 8, 1044-1052.	1.6	47
460	Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach. <i>European Journal of Medicinal Chemistry</i> , 2013, 59, 141-149.	2.6	27
461	Fragment-based drug discovery using NMR spectroscopy. <i>Journal of Biomolecular NMR</i> , 2013, 56, 65-75.	1.6	179
462	Protein-Ligand Interactions: Fundamentals. <i>Methods in Molecular Biology</i> , 2013, 1008, 3-34.	0.4	22
463	Biophysical Screening for the Discovery of Small-Molecule Ligands. <i>Methods in Molecular Biology</i> , 2013, 1008, 357-388.	0.4	59
464	Nanomolar E-Selectin Antagonists with Prolonged Half-Lives by a Fragment-Based Approach. <i>Journal of the American Chemical Society</i> , 2013, 135, 9820-9828.	6.6	53
465	Strategy to Target the Substrate Binding site of SET Domain Protein Methyltransferases. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 681-691.	2.5	18
466	HTS by NMR of Combinatorial Libraries: A Fragment-Based Approach to Ligand Discovery. <i>Chemistry and Biology</i> , 2013, 20, 19-33.	6.2	72
469	Plucking the high hanging fruit: A systematic approach for targeting protein-protein interactions. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 4051-4057.	1.4	67
470	Discovery of Novel STAT3 Small Molecule Inhibitors via in Silico Site-Directed Fragment-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4402-4412.	2.9	83
471	Efficient Synthesis of Molecularly Imprinted Polymers with Enzyme Inhibition Potency by the Controlled Surface Imprinting Approach. <i>ACS Macro Letters</i> , 2013, 2, 566-570.	2.3	69
472	Development of a Plate-Based Optical Biosensor Fragment Screening Methodology to Identify Phosphodiesterase 10A Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3228-3234.	2.9	20
473	Plasmodium Gametocyte Inhibition Identified from a Natural-Product-Based Fragment Library. <i>ACS Chemical Biology</i> , 2013, 8, 2654-2659.	1.6	39
474	Sensitive and Continuous Screening of Inhibitors of $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) at Single SPR Chips. <i>Analytical Chemistry</i> , 2013, 85, 3660-3666.	3.2	42

#	ARTICLE	IF	CITATIONS
475	SIGLEC-4 (MAG) Antagonists: From the Natural Carbohydrate Epitope to Glycomimetics. Topics in Current Chemistry, 2013, 367, 151-200.	4.0	13
476	X-ray Crystallography and Computational Docking for the Detection and Development of Protein-Ligand Interactions. Current Medicinal Chemistry, 2013, 20, 569-575.	1.2	0
477	Advanced Screening to Identify Novel Pesticides. , 2013, , 135-163.		4
478	High-Throughput Fragment Screening by Affinity LC-MS. Journal of Biomolecular Screening, 2013, 18, 160-171.	2.6	36
479	CREDO: a structural interactomics database for drug discovery. Database: the Journal of Biological Databases and Curation, 2013, 2013, bat049.	1.4	35
480	Development of Inhibitors of Plasmodium falciparum Apical Membrane Antigen 1 Based on Fragment Screening. Australian Journal of Chemistry, 2013, 66, 1530.	0.5	20
481	HippDB: a database of readily targeted helical protein-protein interactions. Bioinformatics, 2013, 29, 2806-2807.	1.8	34
482	Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12984-12989.	3.3	97
483	Fragment Screening for the Modelling Community: SPR, ITC, and Crystallography. Australian Journal of Chemistry, 2013, 66, 1507.	0.5	6
485	Evaluation of Potential Genotoxicity of HIV Entry Inhibitors Derived from Natural Sources. PLoS ONE, 2014, 9, e93108.	1.1	5
486	NMR approaches in structure-based lead discovery: Recent developments and new frontiers for targeting multi-protein complexes. Progress in Biophysics and Molecular Biology, 2014, 116, 101-112.	1.4	54
487	The Effects of Combinatorial Chemistry and Technologies on Drug Discovery and Biotechnology – a Mini Review. Nova Biotechnologica Et Chimica, 2014, 13, 87-108.	0.1	7
488	Activity-Limiting Role of Molecular Size: Size-Dependency of Maximum Activity for P450 Inhibition as Revealed by qHTS Data. Drug Metabolism and Disposition, 2014, 42, 1785-1790.	1.7	6
489	Fragment screening by SPR and advanced application to GPCRs. Progress in Biophysics and Molecular Biology, 2014, 116, 113-123.	1.4	63
490	NMR screening of potential inhibitors of methionine S-lyase from Citrobacter freundii. Molecular Biology, 2014, 48, 896-905.	0.4	4
491	Drug discovery in renal disease – towards a more efficient framework. Nature Reviews Nephrology, 2014, 10, 290-296.	4.1	5
492	Knowledge-based Fragment Binding Prediction. PLoS Computational Biology, 2014, 10, e1003589.	1.5	32
493	Lost in Translation (<sc>LiT</sc>): <sc>IUPHAR</sc> Review 6. British Journal of Pharmacology, 2014, 171, 2269-2290.	2.7	9

#	ARTICLE	IF	CITATIONS
494	Use of Sargassum fusiforme Extract and its Bioactive Molecules to inhibit HIV Infection: Bridging Two Paradigms between Eastern and Western Medicine. Chinese Herbal Medicines, 2014, 6, 265-273.	1.2	4
495	Advantages of crystallographic fragment screening: Functional and mechanistic insights from a powerful platform for efficient drug discovery. Progress in Biophysics and Molecular Biology, 2014, 116, 92-100.	1.4	73
496	Harnessing Allostery: A Novel Approach to Drug Discovery. Medicinal Research Reviews, 2014, 34, 1242-1285.	5.0	120
497	Fragment-based inhibitor discovery against $\beta$ -lactamase. Future Medicinal Chemistry, 2014, 6, 413-427.	1.1	18
498	Fragment-Based Approaches to the Discovery of Kinase Inhibitors. Methods in Enzymology, 2014, 548, 69-92.	0.4	13
499	Repositioning the Substrate Activity Screening (SAS) Approach as a Fragment-Based Method for Identification of Weak Binders. ChemBioChem, 2014, 15, 2238-2247.	1.3	7
500	The application of paramagnetic lanthanoid ions in NMR spectroscopy on proteins. Coordination Chemistry Reviews, 2014, 273-274, 2-12.	9.5	79
501	The conformational musings of a medicinal chemist. Drug Discovery Today, 2014, 19, 320-325.	3.2	8
502	Oncogenic protein interfaces: small molecules, big challenges. Nature Reviews Cancer, 2014, 14, 248-262.	12.8	246
503	Insights into drug discovery from natural medicines using reverse pharmacokinetics. Trends in Pharmacological Sciences, 2014, 35, 168-177.	4.0	86
504	NMR-Based Approaches for the Identification and Optimization of Inhibitors of Protein-Protein Interactions. Chemical Reviews, 2014, 114, 4749-4763.	23.0	91
506	De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy. Journal of Chemical Information and Modeling, 2014, 54, 1235-1241.	2.5	54
507	Fragment-Based Lead Discovery and Design. Journal of Chemical Information and Modeling, 2014, 54, 693-704.	2.5	118
508	Discovering Echinococcus granulosus thioredoxin glutathione reductase inhibitors through site-specific dynamic combinatorial chemistry. Molecular Diversity, 2014, 18, 1-12.	2.1	28
509	Kinetic Characterization of Fragment Binding in AmpC $\beta$ -Lactamase by High-Throughput Molecular Simulations. Journal of Chemical Information and Modeling, 2014, 54, 362-366.	2.5	20
510	Theoretical Prediction of Hydrogen-Bond Basicity pKBHX Using Quantum Chemical Topology Descriptors. Journal of Chemical Information and Modeling, 2014, 54, 553-561.	2.5	29
511	molBLOCKS: decomposing small molecule sets and uncovering enriched fragments. Bioinformatics, 2014, 30, 2081-2083.	1.8	32
512	Catalytic activation of pre-substrates via dynamic fragment assembly on protein templates. Nature Communications, 2014, 5, 5170.	5.8	18

#	ARTICLE	IF	CITATIONS
514	Competitive Binding of a Benzimidazole to the Histone-Binding Pocket of the Pygo PHD Finger. <i>ACS Chemical Biology</i> , 2014, 9, 2864-2874.	1.6	60
515	Scalable asymmetric synthesis of a key fragment of Bcl-2/Bcl-xL inhibitors. <i>RSC Advances</i> , 2014, 4, 39817-39821.	1.7	7
516	Lead Discovery and Lead Modification. , 2014, , 19-122.		7
517	In vitro selection of a peptide aptamer that potentiates inhibition of cyclin-dependent kinase 2 by purvalanol. <i>MedChemComm</i> , 2014, 5, 1400-1403.	3.5	11
518	De novo fragment-based design of inhibitors of DXS guided by spin-diffusion-based NMR spectroscopy. <i>Chemical Science</i> , 2014, 5, 3543-3551.	3.7	17
519	Discovery of Potent and Selective Sirtuin 2 (SIRT2) Inhibitors Using a Fragment-Based Approach. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8340-8357.	2.9	74
520	A Simple Fragment of Cyclic Acyldepsipeptides Is Necessary and Sufficient for ClpP Activation and Antibacterial Activity. <i>ChemBioChem</i> , 2014, 15, 2216-2220.	1.3	29
521	C-Terminal Residue Optimization and Fragment Merging: Discovery of a Potent Peptide-Hybrid Inhibitor of Dengue Protease. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1037-1042.	1.3	51
522	How proteins bind macrocycles. <i>Nature Chemical Biology</i> , 2014, 10, 723-731.	3.9	329
523	Regio-controlled synthesis of unsymmetrical pyrazine-fused sinomenine derivatives and discriminate substitution effects on TNF- $\alpha$ inhibitory activity. <i>Tetrahedron</i> , 2014, 70, 5475-5482.	1.0	8
524	Exploring Weak Ligand-Protein Interactions by Long-Lived NMR States: Improved Contrast in Fragment-Based Drug Screening. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 11376-11380.	7.2	69
525	Influence of $\alpha$ -methylation in constructing stapled peptides with olefin metathesis. <i>Tetrahedron</i> , 2014, 70, 7621-7626.	1.0	12
526	Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality. <i>Chemistry and Biology</i> , 2014, 21, 1102-1114.	6.2	865
527	From Catalytic Mechanism to Rational Design of Reversible Covalent Inhibitors of Serine and Cysteine Hydrolases. <i>Israel Journal of Chemistry</i> , 2014, 54, 1137-1151.	1.0	11
528	Small-molecule modulation of Ras signaling. <i>Nature Chemical Biology</i> , 2014, 10, 613-622.	3.9	191
529	The identification, analysis and structure-based development of novel inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2157-2165.	1.4	14
530	Ligand-Free Suzuki-Miyaura Coupling with Sulfur-Modified Gold-Supported Palladium in the Synthesis of a Conformationally-Restricted Cyclopropane Compound Library with Three-Dimensional Diversity. <i>ACS Combinatorial Science</i> , 2014, 16, 215-220.	3.8	24
531	Discovery of Selective Ligands for Telomeric RNA G-quadruplexes (TERRA) through <sup>19</sup> F-NMR Based Fragment Screening. <i>ACS Chemical Biology</i> , 2014, 9, 1559-1566.	1.6	58

#	ARTICLE	IF	CITATIONS
532	Modern Cancer Drug Discovery. , 2014, , 3-53.		8
533	The use of nanopore analysis for discovering drugs which bind to Î±-synuclein for treatment of Parkinson's disease. European Journal of Medicinal Chemistry, 2014, 88, 42-54.	2.6	37
534	A new method for filtering of reactive "warheads" of transition-state analog protease inhibitors. European Journal of Medicinal Chemistry, 2014, 77, 134-138.	2.6	4
535	Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery. Antiviral Research, 2014, 106, 61-70.	1.9	55
536	Biosynthetics: Charting the Future Role of Biocatalysis and Metabolic Engineering in Drug Discovery. Industrial & Engineering Chemistry Research, 2014, 53, 18597-18610.	1.8	3
537	Diamond: shedding light on structure-based drug discovery. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2015, 373, 20140468.	1.6	5
540	Library Design, Chemical Space, and Drug Likeness. , 2015, , 79-98.		0
541	- Library Design, Chemical Space, and Drug Likeness. , 2015, , 96-115.		5
543	A Ligand-observed Mass Spectrometry Approach Integrated into the Fragment Based Lead Discovery Pipeline. Scientific Reports, 2015, 5, 8361.	1.6	28
544	Discovery of Small Molecules that Inhibit the Disordered Protein, p27Kip1. Scientific Reports, 2015, 5, 15686.	1.6	70
547	Identification of Green Tea Catechins as Potent Inhibitors of the Polo-Box Domain of Polo-Like kinase...1. ChemMedChem, 2015, 10, 158-163.	1.6	25
549	Direct Modulation of Small GTPase Activity and Function. Angewandte Chemie - International Edition, 2015, 54, 13516-13537.	7.2	63
550	Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. Angewandte Chemie - International Edition, 2015, 54, 8717-8721.	7.2	33
551	A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets. Frontiers in Neurology, 2015, 6, 197.	1.1	22
552	Identification of Hydrophobic Interfaces in Protein-Ligand Complexes by Selective Saturation Transfer NMR Spectroscopy. Molecules, 2015, 20, 21992-21999.	1.7	3
553	Capturing Nature's Diversity. PLoS ONE, 2015, 10, e0120942.	1.1	35
555	Investigating dynamic interdomain allostery in Pin1. Biophysical Reviews, 2015, 7, 239-249.	1.5	38
556	Flexibility and small pockets at protein-protein interfaces: New insights into druggability. Progress in Biophysics and Molecular Biology, 2015, 119, 2-9.	1.4	118

#	ARTICLE	IF	CITATIONS
557	Fragment growing exploiting dynamic combinatorial chemistry of inhibitors of the aspartic protease endothiapsin. <i>MedChemComm</i> , 2015, 6, 1267-1271.	3.5	19
558	Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6979-6984.	3.3	22
559	Discovery of Nanomolar Dengue and West Nile Virus Protease Inhibitors Containing a 4-Benzoyloxyphenylglycine Residue. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9354-9370.	2.9	86
560	Computational Fragment-Based Drug Design. <i>Methods in Pharmacology and Toxicology</i> , 2015, , 189-215.	0.1	0
561	Design of Novel <i>Mycobacterium tuberculosis</i> Pantothenate Synthetase Inhibitors: Virtual Screening, Synthesis and In Vitro Biological Activities. <i>Molecular Informatics</i> , 2015, 34, 147-159.	1.4	18
562	Fragment Screening and Druggability Assessment for the CBP/p300 KIX Domain through Protein-Observed <sup>19</sup> F-NMR Spectroscopy. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 3735-3739.	7.2	52
563	Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation. <i>Nature Chemistry</i> , 2015, 7, 241-249.	6.6	181
564	Novel encoding methods for DNA-templated chemical libraries. <i>Current Opinion in Chemical Biology</i> , 2015, 26, 25-33.	2.8	28
565	A Virtual Screen Discovers Novel, Fragment-Sized Inhibitors of <i>Mycobacterium tuberculosis</i> InhA. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 645-659.	2.5	35
566	Novel Mcl1/Bcl2 Dual Inhibitors Created by the Structure-Based Hybridization of Drug-Divided Building Blocks and a Fragment Deconstructed from a Known Two-Face BH3 Mimetic. <i>Archiv Der Pharmazie</i> , 2015, 348, 89-99.	2.1	7
567	The Preparation and Characterization of New Antazoline Salts with Dicarboxylic Acids. <i>Molecular Crystals and Liquid Crystals</i> , 2015, 606, 154-164.	0.4	1
568	Computational Challenges of Structure-Based Approaches Applied to HIV. <i>Current Topics in Microbiology and Immunology</i> , 2015, 389, 31-51.	0.7	6
569	State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. <i>Chemical Society Reviews</i> , 2015, 44, 8238-8259.	18.7	132
570	Fragment-Based Drug Discovery. , 2015, , 161-180.		9
571	Protein Crystallography and Drug Discovery. , 2015, , 511-537.		3
572	The solvent component of macromolecular crystals. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2015, 71, 1023-1038.	2.5	47
573	Multiple ligand detection and affinity measurement by ultrafiltration and mass spectrometry analysis applied to fragment mixture screening. <i>Analytica Chimica Acta</i> , 2015, 886, 98-106.	2.6	53
574	Facile construction of 3-indolochromenes and 3-indoloxanthenes via EDDF catalyzed one-pot three component reactions. <i>New Journal of Chemistry</i> , 2015, 39, 6253-6260.	1.4	23

#	ARTICLE	IF	CITATIONS
575	Discovery of microbial natural products by activation of silent biosynthetic gene clusters. <i>Nature Reviews Microbiology</i> , 2015, 13, 509-523.	13.6	762
576	The Purchasable Chemical Space: A Detailed Picture. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 915-924.	2.5	38
577	Carbohydrate-containing Matrix Metalloproteinase Inhibitors (MMPis): A Second Childhood for Sulfonamidic Inhibitors?. <i>RSC Drug Discovery Series</i> , 2015, , 242-254.	0.2	1
578	Generation of a pair of independently binding DNA aptamers in a single round of selection using proximity ligation. <i>Chemical Communications</i> , 2015, 51, 9050-9053.	2.2	7
579	Privileged scaffolds in lead generation. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 781-790.	2.5	71
580	Design and synthesis of analogues of natural products. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 5302-5343.	1.5	132
581	Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2461-2468.	1.0	29
582	Ligand deconstruction: Why some fragment binding positions are conserved and others are not. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2585-94.	3.3	61
583	Classifying shape coverage in fragment libraries using a fingerprinting approach. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2089-2095.	1.0	5
584	Merging Allosteric and Active Site Binding Motifs: De novo Generation of Target Selectivity and Potency via Natural-Product-Derived Fragments. <i>ChemMedChem</i> , 2015, 10, 451-454.	1.6	35
585	Druggability of Intrinsically Disordered Proteins. <i>Advances in Experimental Medicine and Biology</i> , 2015, 870, 383-400.	0.8	52
586	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. <i>Structure</i> , 2015, 23, 2341-2348.	1.6	399
587	Statistical removal of background signals from high-throughput 1H NMR line-broadening ligand-affinity screens. <i>Journal of Biomolecular NMR</i> , 2015, 63, 53-58.	1.6	2
588	Accurate Binding Free Energy Predictions in Fragment Optimization. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 2411-2420.	2.5	119
589	Modeling enzyme-ligand binding in drug discovery. <i>Journal of Cheminformatics</i> , 2015, 7, 48.	2.8	22
590	Novel bivalent inhibitors with sub-nanomolar affinities towards human glyoxalase I. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4724-4727.	1.0	3
591	Navigating into the chemical space between MGCD0103 and SAHA: novel histone deacetylase inhibitors as a promising lead. <i>MedChemComm</i> , 2015, 6, 1816-1825.	3.5	2
592	Computational solvent mapping in structure-based drug design. <i>Future Medicinal Chemistry</i> , 2015, 7, 337-353.	1.1	14

#	ARTICLE	IF	CITATIONS
593	Identification of Noncompetitive Inhibitors of Cytosolic 5â€²-Nucleotidase II Using a Fragment-Based Approach. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9680-9696.	2.9	18
594	Catalystâ€Dependent Selectivity in the Relay Catalytic Branching Cascade. <i>Chemistry - A European Journal</i> , 2015, 21, 2319-2323.	1.7	23
595	DNA display of fragment pairs as a tool for the discovery of novel biologically active small molecules. <i>Chemical Science</i> , 2015, 6, 739-744.	3.7	77
596	Evolutions in fragment-based drug design: the deconstructionâ€reconstruction approach. <i>Drug Discovery Today</i> , 2015, 20, 105-113.	3.2	99
597	Structure-based inhibition of proteinâ€protein interactions. <i>European Journal of Medicinal Chemistry</i> , 2015, 94, 480-488.	2.6	45
598	Cyclic Peptides for Protein-Protein Interaction Targets: Applications to Human Disease. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2016, 26, 199-221.	0.4	33
599	The Role of Biotin in Bacterial Physiology and Virulence: a Novel Antibiotic Target for <i>Mycobacterium tuberculosis</i> . , 2016, , 797-822.		4
600	Structure-Based Ligand Design I. , 2016, , 15-60.		1
601	Identification of a Fragment-Based Scaffold that Inhibits the Glycosyltransferase WaaG from <i>Escherichia coli</i> . <i>Antibiotics</i> , 2016, 5, 10.	1.5	4
602	Process of Fragment-Based Lead Discoveryâ€A Perspective from NMR. <i>Molecules</i> , 2016, 21, 854.	1.7	23
603	Protein-Directed Dynamic Combinatorial Chemistry: A Guide to Protein Ligand and Inhibitor Discovery. <i>Molecules</i> , 2016, 21, 910.	1.7	34
605	Fragment Discovery for the Design of Nitrogen Heterocycles as <i>Mycobacterium tuberculosis</i> Dihydrofolate Reductase Inhibitors. <i>Archiv Der Pharmazie</i> , 2016, 349, 602-613.	2.1	12
606	The Role of Biotin in Bacterial Physiology and Virulence: a Novel Antibiotic Target for <i>Mycobacterium tuberculosis</i> . <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	50
607	Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators. <i>Scientific Reports</i> , 2016, 6, 39454.	1.6	23
608	An Intriguing Correlation Based on the Superimposition of Residue Pairs with Inhibitors that Target Protein-Protein Interfaces. <i>Scientific Reports</i> , 2016, 6, 18543.	1.6	3
609	Discovery of Potent Succinate-Ubiquinone Oxidoreductase Inhibitors via Pharmacophore-linked Fragment Virtual Screening Approach. <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 4830-4837.	2.4	68
610	Structures of endothiapepsinâ€fragment complexes from crystallographic fragment screening using a novel, diverse and affordable 96-compound fragment library. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2016, 72, 346-355.	0.4	29
611	Antibiotikaresistenzen gezielt Ã¼berwinden. <i>Angewandte Chemie</i> , 2016, 128, 6710-6738.	1.6	34



#	ARTICLE	IF	CITATIONS
612	Targeting Antibiotic Resistance. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 6600-6626.	7.2	351
613	Systematic Identification of Protein-Metabolite Interactions in Complex Metabolite Mixtures by Ligand-Detected Nuclear Magnetic Resonance Spectroscopy. <i>Biochemistry</i> , 2016, 55, 2590-2600.	1.2	20
614	Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 533-550.	21.5	806
615	Therapeutic Potential of Spirooxindoles as Antiviral Agents. <i>ACS Infectious Diseases</i> , 2016, 2, 382-392.	1.8	350
616	Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 197-202.	1.0	8
617	A Workflow for Studying Specialized Metabolism in Nonmodel Eukaryotic Organisms. <i>Methods in Enzymology</i> , 2016, 576, 69-97.	0.4	18
618	Badapple: promiscuity patterns from noisy evidence. <i>Journal of Cheminformatics</i> , 2016, 8, 29.	2.8	85
619	Fragment-Based Drug Design Facilitated by Protein-Templated Click Chemistry: Fragment Linking and Optimization of Inhibitors of the Aspartic Protease Endothiapepsin. <i>Chemistry - A European Journal</i> , 2016, 22, 14826-14830.	1.7	16
620	Automatically updating predictive modeling workflows support decision-making in drug design. <i>Future Medicinal Chemistry</i> , 2016, 8, 1779-1796.	1.1	13
621	Structureomics in Systems-Based Drug Discovery. , 2016, , 33-51.		0
622	Microwave-Assisted Branching Cascades: A Route to Diverse 3,4-Dihydroquinazolinone-Embedded Polyheterocyclic Scaffolds. <i>Organic Letters</i> , 2016, 18, 5392-5395.	2.4	14
623	A New Class of Allosteric HIV-1 Integrase Inhibitors Identified by Crystallographic Fragment Screening of the Catalytic Core Domain. <i>Journal of Biological Chemistry</i> , 2016, 291, 23569-23577.	1.6	20
624	Biophysics in drug discovery: impact, challenges and opportunities. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 679-698.	21.5	285
626	Non-competitive inhibitor of nucleoside hydrolase from <i>Leishmania donovani</i> identified by fragment-based drug discovery. <i>RSC Advances</i> , 2016, 6, 87738-87744.	1.7	10
627	Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 186-199.	2.6	21
628	Identification of the minimum pharmacophore of lipid-phosphatidylserine (PS) binding peptide-peptoid hybrid PPS1D1. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4470-4477.	1.4	10
629	Identifying enriched drug fragments as possible candidates for metabolic engineering. <i>BMC Medical Genomics</i> , 2016, 9, 46.	0.7	3
630	Protein-Observed Fluorine NMR Is a Complementary Ligand Discovery Method to <sup>1</sup> H CPMG Ligand-Observed NMR. <i>ACS Chemical Biology</i> , 2016, 11, 3154-3164.	1.6	40

#	ARTICLE	IF	CITATIONS
631	Fragment Linking and Optimization of Inhibitors of the Aspartic Protease Endothiapepsin: Fragment-Based Drug Design Facilitated by Dynamic Combinatorial Chemistry. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 9422-9426.	7.2	55
633	Protein-observed 19F-NMR for fragment screening, affinity quantification and druggability assessment. <i>Nature Protocols</i> , 2016, 11, 1414-1427.	5.5	82
635	Gliptins in managing diabetes - Reviewing computational strategy. <i>Life Sciences</i> , 2016, 166, 108-120.	2.0	27
636	Measurement of Ligand-Target Residence Times by <sup>1</sup> H Relaxation Dispersion NMR Spectroscopy. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10788-10793.	2.9	24
637	Determination of ligand binding modes in weak protein-ligand complexes using sparse NMR data. <i>Journal of Biomolecular NMR</i> , 2016, 66, 195-208.	1.6	19
638	Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. <i>Nature Communications</i> , 2016, 7, 12777.	5.8	67
639	Mycobacterium tuberculosis Malate Synthase Structures with Fragments Reveal a Portal for Substrate/Product Exchange. <i>Journal of Biological Chemistry</i> , 2016, 291, 27421-27432.	1.6	25
640	Oligoioxipiperazines as Topographical Helix Mimetics. <i>Topics in Heterocyclic Chemistry</i> , 2016, , 1-24.	0.2	1
643	Discovery and development of natural product oridonin-inspired anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 102-117.	2.6	132
644	Motif mediated protein-protein interactions as drug targets. <i>Cell Communication and Signaling</i> , 2016, 14, 8.	2.7	76
645	Compound high-quality criteria: a new vision to guide the development of drugs, current situation. <i>Drug Discovery Today</i> , 2016, 21, 573-584.	3.2	32
646	Fragment-Based Discovery of 2-Aminoquinazolin-4(3 <i>H</i> )-ones As Novel Class Nonpeptidomimetic Inhibitors of the Plasmepepsins I, II, and IV. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 374-387.	2.9	55
647	Fragment screening of <i>N</i> -acetylmannosamine kinase reveals noncarbohydrate inhibitors. <i>Canadian Journal of Chemistry</i> , 2016, 94, 920-926.	0.6	6
648	Identification of inhibitors for vascular endothelial growth factor receptor by using dynamic combinatorial chemistry. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1671-1674.	1.0	8
649	Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones. <i>European Journal of Medicinal Chemistry</i> , 2016, 112, 180-195.	2.6	47
650	Hidden entropic contribution in the thermodynamics of molecular complexation. <i>Physical Chemistry Chemical Physics</i> , 2016, 18, 7617-7625.	1.3	5
651	Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. <i>Chemical Research in Toxicology</i> , 2016, 29, 564-616.	1.7	148
652	Structurally Diverse Mitochondrial Branched Chain Aminotransferase (BCATm) Leads with Varying Binding Modes Identified by Fragment Screening. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2452-2467.	2.9	23

#	ARTICLE	IF	CITATIONS
653	Terahertz Devices and Systems for the Spectroscopic Analysis of Biomoleculesâ€”â€™Complexity Great and Smallâ€™. <i>Nanoscience and Technology</i> , 2016, , 131-148.	1.5	0
654	A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain. <i>Chemical Science</i> , 2016, 7, 2322-2330.	3.7	120
655	Tandem buildup of complexity of aromatic molecules through multiple successive electrophile generation in one pot, controlled by varying the reaction temperature. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 1680-1693.	1.5	9
656	BH4 domain of Bcl-2 as a novel target for cancer therapy. <i>Drug Discovery Today</i> , 2016, 21, 989-996.	3.2	51
657	Selective inhibitors of trypanosomal uridylyl transferase RET1 establish druggability of RNA post-transcriptional modifications. <i>RNA Biology</i> , 2017, 14, 611-619.	1.5	5
658	Ligand and Target Discovery by Fragment-Based Screening in Human Cells. <i>Cell</i> , 2017, 168, 527-541.e29.	13.5	330
659	Targeting Oxidative Stress in Stroke. <i>Springer Series in Translational Stroke Research</i> , 2017, , 203-250.	0.1	8
660	Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic targets. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1633-1639.	1.0	41
661	Creating the New from the Old: Combinatorial Libraries Generation with Machine-Learning-Based Compound Structure Optimization. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 133-147.	2.5	12
662	Baicalin positively regulates osteoclast function by activating MAPK/Mitf signalling. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1361-1372.	1.6	20
663	An overview of quinoline as a privileged scaffold in cancer drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 583-597.	2.5	164
664	Data Intensive Genome Level Analysis for Identifying Novel, Non-Toxic Drug Targets for Multi Drug Resistant <i>Mycobacterium tuberculosis</i> . <i>Scientific Reports</i> , 2017, 7, 46595.	1.6	14
665	Matched Molecular Series: Measuring SAR Similarity. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 1187-1196.	2.5	7
666	Allosteric Targeting of the Fanconi Anemia Ubiquitin-Conjugating Enzyme Ube2T by Fragment Screening. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4093-4098.	2.9	30
667	Fragmentâ€™based drug discovery as alternative strategy to the drug development for neglected diseases. <i>Chemical Biology and Drug Design</i> , 2017, 90, 1067-1078.	1.5	17
668	Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5. <i>AAPS Journal</i> , 2017, 19, 1235-1248.	2.2	27
669	Integration on Ligand and Structure Based Approaches in GPCRs. <i>Topics in Medicinal Chemistry</i> , 2017, , 101-161.	0.4	1
670	Surface area, volume and shape descriptors as a novel tool for polymer lead design and discovery. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 102, 188-195.	1.9	7

#	ARTICLE	IF	CITATIONS
671	Reverse Biosynthesis: Generating Combinatorial Pools of Drug Leads from Enzyme-Mediated Fragmentation of Natural Products. <i>ChemBioChem</i> , 2017, 18, 368-373.	1.3	4
672	Recent advances on the encoding and selection methods of DNA-encoded chemical library. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 361-369.	1.0	57
673	STD-NMR experiments identify a structural motif with novel second-site activity against West Nile virus NS2B-NS3 protease. <i>Antiviral Research</i> , 2017, 146, 174-183.	1.9	6
674	Crystal structure and functional characterization of <i>SF</i> 216 from <i>Shigella flexneri</i> . <i>FEBS Letters</i> , 2017, 591, 3692-3703.	1.3	1
675	CRISPR-Cas-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 11751-11756.	3.3	50
676	Discovery of Potent Orally Active Protease-Activated Receptor 1 (PAR1) Antagonists Based on Andrographolide. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7166-7185.	2.9	16
677	A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein-Protein Interaction Interfaces. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 2250-2272.	2.5	14
678	Towards detecting regulatory protein-metabolite interactions. <i>Current Opinion in Microbiology</i> , 2017, 39, 16-23.	2.3	42
679	Label-free NMR-based dissociation kinetics determination. <i>Journal of Biomolecular NMR</i> , 2017, 69, 229-235.	1.6	9
680	Topological pattern for the search of new active drugs against methicillin resistant <i>Staphylococcus aureus</i> . <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 807-815.	2.6	16
681	A highly efficient and recyclable silica-supported tungstic acid (STA) catalyst for the synthesis of pyrano[3,2-c]chromen-5-ones under solvent free conditions. <i>Tetrahedron</i> , 2017, 73, 5163-5169.	1.0	36
682	Partial filling affinity capillary electrophoresis as a useful tool for fragment-based drug discovery: A proof of concept on thrombin. <i>Analytica Chimica Acta</i> , 2017, 984, 211-222.	2.6	17
683	Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 527-553.	2.9	103
684	Dynamic undocking and the quasi-bound state as tools for drug discovery. <i>Nature Chemistry</i> , 2017, 9, 201-206.	6.6	68
685	Catalytic Branching Cascades in Diversity Oriented Synthesis. <i>ChemCatChem</i> , 2017, 9, 30-40.	1.8	13
686	Discovery of novel dengue virus NS5 methyltransferase non-nucleoside inhibitors by fragment-based drug design. <i>European Journal of Medicinal Chemistry</i> , 2017, 125, 865-880.	2.6	74
687	Quantitative Characterization of the Binding and Unbinding of Millimolar Drug Fragments with Molecular Dynamics Simulations. <i>Journal of Chemical Theory and Computation</i> , 2017, 13, 3372-3377.	2.3	115
688	IN SILICO STUDIES FOR VARIOUS ANTIBACTERIAL BENZIL AND ITS SUBSTITUTED ANALOGS. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2017, 10, 186.	0.3	0

#	ARTICLE	IF	CITATIONS
689	Drug discovery. , 2017, , 281-420.		1
690	Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry. IUCr, 2017, 4, 308-321.	1.0	65
691	Current perspectives in fragment-based lead discovery (FBLD). Essays in Biochemistry, 2017, 61, 453-464.	2.1	122
692	Fragment-Based Drug Design: Strategic Advances and Lessons Learned. , 2017, , 212-232.		9
693	Self-Assembled Receptors for Protein Surface Recognition. , 2017, , 351-369.		0
694	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. , 2017, , 64-93.		0
695	DOCKING STUDIES FOR VARIOUS ANTIBACTERIAL BENZILATE DERIVATIVES. Asian Journal of Pharmaceutical and Clinical Research, 2017, 10, 268.	0.3	3
696	DOCKING ANTIOXIDANT ACTIVITY ON HYDROXY (DIPHENYL) ACETICACID AND ITS DERIVATIVES. Asian Journal of Pharmaceutical and Clinical Research, 2017, 10, 263.	0.3	4
698	Binding Modes of Ligands Using Enhanced Sampling (BLUES): Rapid Decorrelation of Ligand Binding Modes via Nonequilibrium Candidate Monte Carlo. Journal of Physical Chemistry B, 2018, 122, 5579-5598.	1.2	53
699	Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications. AAPS Journal, 2018, 20, 59.	2.2	67
700	A Fragment Library Screening Approach to Identify Selective Inhibitors against an Essential Fungal Enzyme. SLAS Discovery, 2018, 23, 520-531.	1.4	7
701	Binding-Site Compatible Fragment Growing Applied to the Design of $\hat{I}^2$ -Adrenergic Receptor Ligands. Journal of Medicinal Chemistry, 2018, 61, 1118-1129.	2.9	39
702	Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis. ChemMedChem, 2018, 13, 1377-1386.	1.6	10
703	Success stories of natural product-based hybrid molecules for multi-factorial diseases. European Journal of Medicinal Chemistry, 2018, 151, 62-97.	2.6	65
704	Identification of small-molecule inhibitors of USP2a. European Journal of Medicinal Chemistry, 2018, 150, 261-267.	2.6	24
705	Solvent-free synthesis of 4H-pyranonaphthoquinones using highly active and stable polymer-grafted layered double hydroxides (LDHs-g-POEGMA) as an efficient and reusable heterogeneous catalyst. Research on Chemical Intermediates, 2018, 44, 517-533.	1.3	7
706	Enhancing large-scale docking simulation on heterogeneous systems: An MPI vs rCUDA study. Future Generation Computer Systems, 2018, 79, 26-37.	4.9	12
707	Fractal behavior and shape characteristics of fragments produced by the impact of quasi-brittle spheres. Powder Technology, 2018, 325, 498-509.	2.1	27

#	ARTICLE	IF	CITATIONS
708	Negishi cross-couplings in the synthesis of amino acids. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 10-20.	1.5	41
709	<sup>19</sup> F multiple-quantum coherence NMR spectroscopy for probing protein-ligand interactions. <i>RSC Advances</i> , 2018, 8, 40687-40692.	1.7	3
710	Imaginative Order from Reasonable Chaos: Conformation-Driven Activity and Reactivity in Exploring Protein-Ligand Interactions. <i>Australian Journal of Chemistry</i> , 2018, 71, 917.	0.5	0
711	Look and Outlook on Enzyme-Mediated Macrolide Resistance. <i>Frontiers in Microbiology</i> , 2018, 9, 1942.	1.5	69
712	Allosteric Inhibition of a Mammalian Lectin. <i>Journal of the American Chemical Society</i> , 2018, 140, 14915-14925.	6.6	35
713	Energy-based tuning of metaheuristics for molecular docking on multi-CPU. <i>Concurrency Computation Practice and Experience</i> , 2018, 30, e4684.	1.4	6
714	Impact of Molecular Descriptors on Computational Models. <i>Methods in Molecular Biology</i> , 2018, 1825, 171-209.	0.4	34
715	Enzyme-like Click Catalysis by a Copper-Containing Single-Chain Nanoparticle. <i>Journal of the American Chemical Society</i> , 2018, 140, 13695-13702.	6.6	100
716	Methyl group reorientation under ligand binding probed by pseudocontact shifts. <i>Journal of Biomolecular NMR</i> , 2018, 71, 275-285.	1.6	16
717	The Science and Technology Challenge: How to Find New Drugs. , 2018, , 41-61.		0
718	Synthesis, Reactivity, Functionalization, and ADMET Properties of Silicon-Containing Nitrogen Heterocycles. <i>Journal of the American Chemical Society</i> , 2018, 140, 6668-6684.	6.6	80
719	On the Implication of Water on Fragment-Ligand Growth in Kinase Binding Thermodynamics. <i>ChemMedChem</i> , 2018, 13, 1988-1996.	1.6	8
720	Discovery of fragments that target key interactions in the signal recognition particle (SRP) as potential leads for a new class of antibiotics. <i>PLoS ONE</i> , 2018, 13, e0200387.	1.1	7
721	Chemistry-driven Hit-to-Lead Optimization Guided by Structure-based Approaches. <i>Molecular Informatics</i> , 2018, 37, e1800059.	1.4	33
722	Drug-Drug and Drug-Nutraceutical Cocrystal/Salt as Alternative Medicine for Combination Therapy: A Crystal Engineering Approach. <i>Crystals</i> , 2018, 8, 101.	1.0	111
724	Accelerating Drugs Discovery with Deep Reinforcement Learning. , 2018, , .		4
725	PADFrag: A Database Built for the Exploration of Bioactive Fragment Space for Drug Discovery. <i>Journal of Chemical Information and Modeling</i> , 2018, 58, 1725-1730.	2.5	45
726	Proposing novel TNF± direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline. <i>Journal of Molecular Graphics and Modelling</i> , 2018, 85, 111-121.	1.3	8

#	ARTICLE	IF	CITATIONS
727	Small molecule-based targeting of TTD-A dimerization to control TFIH transcriptional activity represents a potential strategy for anticancer therapy. <i>Journal of Biological Chemistry</i> , 2018, 293, 14974-14988.	1.6	12
728	A Fragment-Based Approach for the Development of G-Quadruplex Ligands: Role of the Amidoxime Moiety. <i>Molecules</i> , 2018, 23, 1874.	1.7	7
729	Synthesis and spectroscopic characterization of cyclobutyl hydantoins. <i>Journal of Molecular Structure</i> , 2018, 1171, 495-502.	1.8	3
730	Structural Insights on Fragment Binding Mode Conservation. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5963-5973.	2.9	21
731	Comparative Evaluation of Covalent Docking Tools. <i>Journal of Chemical Information and Modeling</i> , 2018, 58, 1441-1458.	2.5	101
732	In Silico Tools and Databases for Designing Peptide-Based Vaccine and Drugs. <i>Advances in Protein Chemistry and Structural Biology</i> , 2018, 112, 221-263.	1.0	49
733	Zirconyl Hydrogenphosphate Nanocontainers for Flexible Transport and Release of Lipophilic Cytostatics, Insecticides, and Antibiotics. <i>Advanced Functional Materials</i> , 2019, 29, 1900543.	7.8	9
734	Drugging an undruggable pocket on KRAS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15823-15829.	3.3	280
735	Smart polymers for biomimetic catalysis and enzyme inhibition. , 2019, , 33-49.		1
736	Designing DNA Encoded Libraries of Diverse Products in a Focused Property Space. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 4645-4653.	2.5	26
737	Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs. <i>Nature Chemistry</i> , 2019, 11, 1113-1123.	6.6	93
738	Designing compact training sets for data-driven molecular property prediction through optimal exploitation and exploration. <i>Molecular Systems Design and Engineering</i> , 2019, 4, 1048-1057.	1.7	15
739	Natural Products in the "Marketplace": Interfacing Synthesis and Biology. <i>Journal of the American Chemical Society</i> , 2019, 141, 3332-3346.	6.6	52
740	Fragment-based drug design of nature-inspired compounds. <i>Physical Sciences Reviews</i> , 2019, 4, .	0.8	3
741	Crystal structure of the SPRY domain of human SPSB2 in the apo state. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2019, 75, 412-418.	0.4	2
742	KRAS Binders Hidden in Nature. <i>Chemistry - A European Journal</i> , 2019, 25, 12037-12041.	1.7	17
743	Discovery of a Novel Series of Tricyclic Oxadiazine 4a-Methyl Esters Based on Indoxacarb as Potential Sodium Channel Blocker/Modulator Insecticides. <i>Journal of Agricultural and Food Chemistry</i> , 2019, 67, 7793-7809.	2.4	10
744	Spirocycles as Rigidified sp <sup>3</sup> -Rich Scaffolds for a Fragment Collection. <i>Organic Letters</i> , 2019, 21, 4600-4604.	2.4	35

#	ARTICLE	IF	CITATIONS
745	Cell wall peptidoglycan in <i>Mycobacterium tuberculosis</i> : An Achilles' heel for the TB-causing pathogen. <i>FEMS Microbiology Reviews</i> , 2019, 43, 548-575.	3.9	131
746	Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening. <i>Journal of the American Chemical Society</i> , 2019, 141, 8951-8968.	6.6	213
747	Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2905-2913.	1.4	14
748	MDA-9/Syntenin: An emerging global molecular target regulating cancer invasion and metastasis. <i>Advances in Cancer Research</i> , 2019, 144, 137-191.	1.9	17
749	Ligand retargeting by binding site analogy. <i>European Journal of Medicinal Chemistry</i> , 2019, 175, 107-113.	2.6	2
750	Can One Trust Kinetic and Thermodynamic Observables from Biased Metadynamics Simulations?: Detailed Quantitative Benchmarks on Millimolar Drug Fragment Dissociation. <i>Journal of Physical Chemistry B</i> , 2019, 123, 3672-3678.	1.2	34
751	Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies. <i>SLAS Discovery</i> , 2019, 24, 440-456.	1.4	7
752	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 974-977.	1.0	12
753	GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 59-82.	21.5	179
754	Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1. <i>European Journal of Medicinal Chemistry</i> , 2019, 161, 479-492.	2.6	15
755	NAOMInext – Synthetically feasible fragment growing in a structure-based design context. <i>European Journal of Medicinal Chemistry</i> , 2019, 163, 747-762.	2.6	10
756	Methodology of drug screening and target identification for new necroptosis inhibitors. <i>Journal of Pharmaceutical Analysis</i> , 2019, 9, 71-76.	2.4	10
757	Ligand-Based Fluorine NMR Screening: Principles and Applications in Drug Discovery Projects. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2218-2244.	2.9	115
758	Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs. <i>Briefings in Bioinformatics</i> , 2020, 21, 649-662.	3.2	139
759	Plant natural fragments, an innovative approach for drug discovery. <i>Phytochemistry Reviews</i> , 2020, 19, 1141-1156.	3.1	5
760	Silica-supported tungstic acid (STA): A recyclable catalyst for the synthesis of 1H-indazolo [1,2-b]phthalazine-trione and spiro-triazolo[1,2-a]indazole-tetraone derivatives under solvent-free condition. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , 2020, 195, 201-210.	0.8	3
761	Flexible Fragment Growing Boosts Potency of Quorum-Sensing Inhibitors against <i>Pseudomonas aeruginosa</i> Virulence. <i>ChemMedChem</i> , 2020, 15, 188-194.	1.6	23
762	Design, synthesis and biological evaluation of imidazole and oxazole fragments as HIV-1 integrase-LEDGF/p75 disruptors and inhibitors of microbial pathogens. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115210.	1.4	18



#	ARTICLE	IF	CITATIONS
763	Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2). <i>Biochemistry</i> , 2020, 59, 563-581.	1.2	28
764	Identifying Ortholog Selective Fragment Molecules for Bacterial Glutaredoxins by NMR and Affinity Enhancement by Modification with an Acrylamide Warhead. <i>Molecules</i> , 2020, 25, 147.	1.7	3
765	QN-Docking: An innovative molecular docking methodology based on Q-Networks. <i>Applied Soft Computing Journal</i> , 2020, 96, 106678.	4.1	10
766	SyntaLinker: automatic fragment linking with deep conditional transformer neural networks. <i>Chemical Science</i> , 2020, 11, 8312-8322.	3.7	72
767	Shape-Based Descriptors for Efficient Structure-Based Fragment Growing. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 6269-6281.	2.5	5
768	Multimodal small-molecule screening for human prion protein binders. <i>Journal of Biological Chemistry</i> , 2020, 295, 13516-13531.	1.6	14
769	Kinetics and free energy of ligand dissociation using weighted ensemble milestoning. <i>Journal of Chemical Physics</i> , 2020, 153, 154117.	1.2	10
770	Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 213.	7.1	387
771	Proteomimetic surface fragments distinguish targets by function. <i>Chemical Science</i> , 2020, 11, 10390-10398.	3.7	5
772	Strategies for Discovering New Antibiotics from Bacteria in the Post-Genomic Era. <i>Current Microbiology</i> , 2020, 77, 3213-3223.	1.0	7
773	Visualizing drug binding interactions using microcrystal electron diffraction. <i>Communications Biology</i> , 2020, 3, 417.	2.0	25
774	Design of Non-Haemolytic Nanoemulsions for Intravenous Administration of Hydrophobic APIs. <i>Pharmaceutics</i> , 2020, 12, 1141.	2.0	12
775	Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach. <i>Scientific Reports</i> , 2020, 10, 19125.	1.6	47
776	Small Molecule Inhibitors Targeting the Interaction of Ricin Toxin A Subunit with Ribosomes. <i>ACS Infectious Diseases</i> , 2020, 6, 1894-1905.	1.8	9
777	Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7052-7065.	2.9	8
778	Fragment Linking Strategies for Structure-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11420-11435.	2.9	53
779	Competition NMR for Detection of Hit/Lead Inhibitors of Protein-Protein Interactions. <i>Molecules</i> , 2020, 25, 3017.	1.7	11
780	The rise of molecular simulations in fragment-based drug design (FBDD): an overview. <i>Drug Discovery Today</i> , 2020, 25, 1693-1701.	3.2	29

#	ARTICLE	IF	CITATIONS
781	A Modular Approach to Dibenzo-fused $\beta$ -Lactams: Palladium-Catalyzed Bridging $C-H$ Activation. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 18261-18266.	7.2	35
782	A Modular Approach to Dibenzo-fused $\beta$ -Lactams: Palladium-Catalyzed Bridging $C-H$ Activation. <i>Angewandte Chemie</i> , 2020, 132, 18418-18423.	1.6	8
783	Acyldepsipeptide Antibiotics and a Bioactive Fragment Thereof Differentially Perturb <i>Mycobacterium tuberculosis</i> ClpXP1P2 Activity <i>in Vitro</i> . <i>ACS Chemical Biology</i> , 2023, 18, 724-733.	1.6	12
784	Novel, Self-Assembling Dimeric Inhibitors of Human $\beta$ 2 Tryptase. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3004-3027.	2.9	29
787	DNA Encoded Libraries: A Visitor's Guide. <i>Israel Journal of Chemistry</i> , 2020, 60, 268-280.	1.0	51
788	Covalent fragment libraries in drug discovery. <i>Drug Discovery Today</i> , 2020, 25, 983-996.	3.2	65
789	5-Arylidene-2-(4-hydroxyphenyl)aminothiazolones with selective inhibitory activity against some leukemia cell lines. <i>Archiv Der Pharmazie</i> , 2021, 354, 2000342.	2.1	5
790	The future of covalent inhibition. <i>Annual Reports in Medicinal Chemistry</i> , 2021, 56, 267-284.	0.5	0
791	Emerging roles of SIRT6 in human diseases and its modulators. <i>Medicinal Research Reviews</i> , 2021, 41, 1089-1137.	5.0	75
792	Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 163, 130-142.	1.4	21
793	Targeting protein-protein interactions in the DNA damage response pathways for cancer chemotherapy. <i>RSC Chemical Biology</i> , 2021, 2, 1167-1195.	2.0	14
794	Photoaffinity labelling strategies for mapping the small molecule-protein interactome. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 7792-7809.	1.5	39
795	Generative chemistry: drug discovery with deep learning generative models. <i>Journal of Molecular Modeling</i> , 2021, 27, 71.	0.8	63
796	Macromolecular crystallography using microcrystal electron diffraction. <i>Acta Crystallographica Section D: Structural Biology</i> , 2021, 77, 313-324.	1.1	9
797	Fragment-Based Nuclear Magnetic Resonance Screen against a Regulator of G Protein Signaling Identifies a Binding "Hot Spot". <i>ChemBioChem</i> , 2021, 22, 1609-1620.	1.3	2
798	Substituted 3-R-2,8-Dioxo-7,8-dihydro-2H-pyrrolo[1,2-a][1,2,4] triazino [2,3-c]quinazoline-5a(6H)carboxylic Acids and their Salts " a Promising Class of Anti-inflammatory Agents. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2021, 20, 75-88.	1.1	2
799	Call for Papers for the Special Issue: From Reaction Informatics to Chemical Space. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 1531-1532.	2.5	3
800	MCSS-Based Predictions of Binding Mode and Selectivity of Nucleotide Ligands. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 2599-2618.	2.3	2

#	ARTICLE	IF	CITATIONS
801	Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19. <i>Journal of General Virology</i> , 2021, 102, .	1.3	60
802	Chemoproteomic-enabled phenotypic screening. <i>Cell Chemical Biology</i> , 2021, 28, 371-393.	2.5	20
805	Inspecting the Mechanism of Fragment Hits Binding on SARS-CoV-2 M <sup>pro</sup> by Using Supervised Molecular Dynamics (SuMD) Simulations. <i>ChemMedChem</i> , 2021, 16, 2075-2081.	1.6	12
806	DNA-Encoded Chemical Libraries: A Comprehensive Review with Successful Stories and Future Challenges. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1265-1279.	2.5	120
809	An Experimental Toolbox for Structure-Based Hit Discovery for <i>Pseudomonas aeruginosa</i> FabF, a Promising Target for Antibiotics. <i>ChemMedChem</i> , 2021, 16, 2715-2726.	1.6	6
810	Exploring and mapping chemical space with molecular assembly trees. <i>Science Advances</i> , 2021, 7, eabj2465.	4.7	13
811	Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 45, 116328.	1.4	17
812	Development of a multi-layering protein grafting process on miniaturized monolithic columns for weak affinity nano liquid chromatography application purposes. <i>Journal of Chromatography A</i> , 2021, 1657, 462567.	1.8	1
813	Automated affinity selection for rapid discovery of peptide binders. <i>Chemical Science</i> , 2021, 12, 10817-10824.	3.7	10
814	Saturation Transfer Difference NMR for Fragment Screening. <i>Current Protocols in Chemical Biology</i> , 2013, 5, 251-268.	1.7	17
816	Fragmentverknüpfung und Optimierung von Hemmstoffen der Aspartylprotease Endothiapepsin: Fragmentbasiertes Wirkstoffdesign beschleunigt durch dynamische kombinatorische Chemie. <i>Angewandte Chemie</i> , 2016, 128, 9569-9574.	1.6	21
817	Alchemical free energy calculations via metadynamics: Application to the theophylline-RNA aptamer complex. <i>Journal of Computational Chemistry</i> , 2020, 41, 1804-1819.	1.5	10
818	Structure-Guided Discovery of New Antimicrobial Agents. , 2012, , 969-984.		1
819	NMR Screening in Fragment-Based Drug Design: A Practical Guide. <i>Methods in Molecular Biology</i> , 2015, 1263, 197-208.	0.4	8
820	Biophysical Methods for Identifying Fragment-Based Inhibitors of Protein-Protein Interactions. <i>Methods in Molecular Biology</i> , 2015, 1278, 587-613.	0.4	15
821	NMR Metabolomics Protocols for Drug Discovery. <i>Methods in Molecular Biology</i> , 2019, 2037, 265-311.	0.4	16
822	Crystallographic Fragment Screening. <i>Methods in Molecular Biology</i> , 2012, 841, 161-177.	0.4	13
823	Evaluation of Plasma Membrane Calcium/Calmodulin-Dependent ATPase Isoform 4 as a Potential Target for Fertility Control. <i>Handbook of Experimental Pharmacology</i> , 2010, , 79-95.	0.9	7

#	ARTICLE	IF	CITATIONS
824	Molecular Modeling. , 2015, , 93-128.		2
825	General Theory of Fragment Linking in Molecular Design: Why Fragment Linking Rarely Succeeds and How to Improve Outcomes. Journal of Chemical Theory and Computation, 2021, 17, 450-462.	2.3	21
826	Ligand-detected NMR Methods in Drug Discovery. RSC Drug Discovery Series, 2017, , 23-43.	0.2	2
827	Chapter 8. Fluorescent Thermal Shift Assays for Identifying Small Molecule Ligands. RSC Drug Discovery Series, 0, , 208-238.	0.2	2
828	Chapter 7. Fragment-based De Novo Design of Drug-like Molecules. , 2008, , 217-239.		3
831	Identifying ligand-binding hot spots in proteins using brominated fragments. Acta Crystallographica Section F: Structural Biology Communications, 2013, 69, 1060-1065.	0.7	10
832	Exhaustive sampling of the fragment space associated to a molecule leading to the generation of conserved fragments. Chemical Biology and Drug Design, 2018, 91, 655-667.	1.5	7
833	Using Fragment-Based Approaches to Discover New Antibiotics. SLAS Discovery, 2018, 23, 495-510.	1.4	20
834	Predicting Allosteric Effects from Orthosteric Binding in Hsp90-Ligand Interactions: Implications for Fragment-Based Drug Design. PLoS Computational Biology, 2016, 12, e1004840.	1.5	21
835	Discovery of Fragment Molecules That Bind the Human Peroxiredoxin 5 Active Site. PLoS ONE, 2010, 5, e9744.	1.1	22
836	Ligand-Induced Protein Mobility in Complexes of Carbonic Anhydrase II and Benzenesulfonamides with Oligoglycine Chains. PLoS ONE, 2013, 8, e57629.	1.1	2
837	Computer-Aided Design of Fragment Mixtures for NMR-Based Screening. PLoS ONE, 2013, 8, e58571.	1.1	15
838	Exploring the Chemical Space around 8-Mercaptoguanine as a Route to New Inhibitors of the Folate Biosynthesis Enzyme HPPK. PLoS ONE, 2013, 8, e59535.	1.1	17
839	Virtual and Biophysical Screening Targeting the $\beta$ -Tubulin Complex – A New Target for the Inhibition of Microtubule Nucleation. PLoS ONE, 2013, 8, e63908.	1.1	13
840	Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2. PLoS ONE, 2013, 8, e65689.	1.1	23
841	Freely Accessible Chemical Database Resources of Compounds for In Silico Drug Discovery. Current Medicinal Chemistry, 2020, 26, 7581-7597.	1.2	9
842	Probing a Chemical Space for Fragmental Topology-Activity Landscapes (FRAGTAL): Application for Diketo Acid and Catechol HIV Integrase Inhibitor Offspring Fragments. Combinatorial Chemistry and High Throughput Screening, 2013, 16, 274-287.	0.6	4
843	Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery. Current Topics in Medicinal Chemistry, 2016, 16, 2107-2114.	1.0	21

#	ARTICLE	IF	CITATIONS
844	Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery. Current Topics in Medicinal Chemistry, 2016, 17, 4-15.	1.0	60
845	Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer. Current Topics in Medicinal Chemistry, 2019, 19, 457-466.	1.0	3
846	Chemical Intuition in Drug Design and Discovery. Current Topics in Medicinal Chemistry, 2019, 19, 1679-1693.	1.0	10
847	A Review of MED-SuMo Applications. Infectious Disorders - Drug Targets, 2009, 9, 344-357.	0.4	16
848	Structural Studies of the Complex Between Akt-in and the Akt2-PH Domain Suggest that the Peptide Acts as an Allosteric Inhibitor of the Akt Kinase. The Open Spectroscopy Journal, 2009, 3, 65-76.	1.0	1
849	Targets in Epigenetics: Inhibiting the Methyl Writers of the Histone Code. Current Chemical Genomics, 2011, 5, 72-84.	2.0	52
850	Epigenetic approaches to psychiatric disorders. Dialogues in Clinical Neuroscience, 2010, 12, 25-35.	1.8	89
851	Fragment-Based Phenotypic Lead Discovery To Identify New Drug Seeds That Target Infectious Diseases. ACS Chemical Biology, 2021, 16, 2158-2163.	1.6	6
852	Development of Specific Gamma Secretase Inhibitors. , 2009, , 423-437.		0
853	Screening-Technologien zur Leitstruktursuche. , 2009, , 97-112.		0
854	Chapter 8. Drug Discovery by DNA-encoded Libraries. RSC Drug Discovery Series, 2010, , 258-302.	0.2	0
858	Discovery of NVP-AUY922. RSC Drug Discovery Series, 2013, , 213-240.	0.2	0
859	Hydroxamates as Ribonucleotide Reductase Inhibitors. , 2013, , 153-172.		0
860	Adventures in Small Molecule Fragment Screening by X-ray Crystallography. NATO Science for Peace and Security Series A: Chemistry and Biology, 2015, , 197-208.	0.5	0
861	CHAPTER 10. Fragment-Based Approaches to Epigenetic Targets. RSC Drug Discovery Series, 2015, , 238-258.	0.2	0
862	Virtual Fragment Preparation for Computational Fragment-Based Drug Design. Methods in Molecular Biology, 2015, 1289, 31-41.	0.4	0
863	Generating "Fragment-Based Virtual Library" Using Pocket Similarity Search of Ligand-Receptor Complexes. Methods in Molecular Biology, 2015, 1289, 23-29.	0.4	0
864	Creation of innovative drugs (approaches and methodology of drug design) "one of the main issues of the modern pharmaceutical education. Journal of Organic and Pharmaceutical Chemistry, 2015, 13, 49-58.	0.0	1

#	ARTICLE	IF	CITATIONS
865	Molecular Modelling, Dynamics, and Docking of Membrane Proteins. Advances in Medical Technologies and Clinical Practice Book Series, 2016, , 186-208.	0.3	0
866	Chapter 14 Perfluorocarbon Theranostic Nanomedicines: Pharmaceutical Scientistâ€™s Perspective. , 2016, , 407-432.		0
867	Topical Drug Candidate Selection Criteria and Cascade. , 2017, , 115-131.		2
868	Molecular Modelling, Dynamics, and Docking of Membrane Proteins. , 2017, , 747-769.		0
869	Fragment-based drug design (FBDD). Journal of Organic and Pharmaceutical Chemistry, 2017, 15, 28-44.	0.0	1
870	Paramagnetic NMR in Drug Discovery. New Developments in NMR, 2018, , 258-282.	0.1	0
872	Lead Optimization in the Drug Discovery Process. Advances in Medical Technologies and Clinical Practice Book Series, 2019, , 62-79.	0.3	1
873	Drug Discovery and Development. , 2019, , 87-136.		0
876	Chapter 6. Structure-based PROTAC Design. RSC Drug Discovery Series, 2020, , 115-134.	0.2	0
879	Utility of chemical probes for mass spectrometry based chemical proteomics. , 2022, , 129-156.		0
880	Substituted pyrrolo[1,2-a][1,2,4]triazolo-(triazino-)[c]quinazolines - a promising class of lipoxygenase inhibitors. Aktualnâ€™ Pitannâ€™ Farmaceutiâ€™ Mediâ€™ Nauki Ta Praktiki, 2020, .	0.0	0
884	Computer applications for prediction of protein-protein interactions and rational drug design. Advances and Applications in Bioinformatics and Chemistry, 2009, 2, 101-23.	1.6	9
887	Current Trends in SPR Biosensing of SARS-CoV-2 Entry Inhibitors. Chemosensors, 2021, 9, 330.	1.8	6
888	Structure-based proteinâ€™ligand interaction fingerprints for binding affinity prediction. Computational and Structural Biotechnology Journal, 2021, 19, 6291-6300.	1.9	14
890	MicroED: conception, practice and future opportunities. IUCr, 2022, 9, 169-179.	1.0	10
891	Inverse design of 3d molecular structures with conditional generative neural networks. Nature Communications, 2022, 13, 973.	5.8	70
892	Fragment-Based Drug Discovery for <i>Trypanosoma brucei</i> Glycosylphosphatidylinositol-Specific Phospholipase C through Biochemical and WaterLOGSY-NMR Methods. Journal of Biochemistry, 2022, , .	0.9	1
893	How does a small molecule bind at a cryptic binding site?. PLoS Computational Biology, 2022, 18, e1009817.	1.5	21

#	ARTICLE	IF	CITATIONS
894	Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 17728-17743.	2.9	29
895	Development of Computational Approaches with a Fragment-Based Drug Design Strategy: In Silico Hsp90 Inhibitors Discovery. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13226.	1.8	2
896	A deep generative model for molecule optimization via one fragment modification. <i>Nature Machine Intelligence</i> , 2021, 3, 1040-1049.	8.3	26
897	Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from <i>Mycobacterium tuberculosis</i> : A Crystallographic and Molecular Modelling Study. <i>Pharmaceutics</i> , 2021, 14, 1282.	1.7	2
898	Chapter 11. Application of Molecular Modelling to Speed-up the Lead Discovery Process. <i>Chemical Biology</i> , 0, , 281-316.	0.1	0
901	Computer-aided identification of potential inhibitors against <i>Necator americanus</i> glutathione S-transferase 3. <i>Informatics in Medicine Unlocked</i> , 2022, 30, 100957.	1.9	1
902	Tools shaping drug discovery and development. <i>Biophysics Reviews</i> , 2022, 3, .	1.0	3
903	The application of zebrafish patient-derived xenograft tumor models in the development of antitumor agents. <i>Medicinal Research Reviews</i> , 2023, 43, 212-236.	5.0	5
904	<sup>19</sup> F chemical library and <sup>19</sup> F-NMR for a weakly bound complex structure. <i>RSC Medicinal Chemistry</i> , 2022, 13, 1100-1111.	1.7	2
905	Characterizing Conformational Diversity of G Protein-coupled Receptors by Solution NMR Spectroscopy. <i>New Developments in NMR</i> , 2022, , 346-382.	0.1	0
906	On drug discovery against infectious diseases and academic medicinal chemistry contributions. <i>Beilstein Journal of Organic Chemistry</i> , 0, 18, 1355-1378.	1.3	0
907	Fragment-Based and Structural Investigation for Discovery of JNK3 Inhibitors. <i>Pharmaceutics</i> , 2022, 14, 1900.	2.0	2
908	Functional-Unit-Based Material Design: Ultralow Thermal Conductivity in Thermoelectrics with Linear Triatomic Resonant Bonds. <i>Journal of the American Chemical Society</i> , 2022, 144, 18552-18561.	6.6	14
910	The IQA Energy Partition in a Drug Design Setting: A Hepatitis C Virus RNA-Dependent RNA Polymerase (NS5B) Case Study. <i>Pharmaceutics</i> , 2022, 15, 1237.	1.7	1
911	Fragment-Based Dynamic Combinatorial Chemistry for Identification of Selective $\alpha$ -Glucosidase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 1791-1796.	1.3	2
912	Small bioactive molecules designed to be probes as baits "fishing out" cellular targets: Finding the fish in the proteome sea. <i>Chinese Journal of Analytical Chemistry</i> , 2023, 51, 100196.	0.9	0
913	Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. <i>Molecules</i> , 2022, 27, 8282.	1.7	0
914	Antibiotic discovery in the artificial intelligence era. <i>Annals of the New York Academy of Sciences</i> , 2023, 1519, 74-93.	1.8	13

#	ARTICLE	IF	CITATIONS
916	The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development. Molecular Biomedicine, 2022, 3, .	1.7	4
917	Exploring the structure, function of thiamine pyrophosphate riboswitch, and designing small molecules for antibacterial activity. Wiley Interdisciplinary Reviews RNA, 0, , .	3.2	1
918	Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target. ACS Chemical Biology, 2023, 18, 251-264.	1.6	2
919	Ligand Gaussian Accelerated Molecular Dynamics 2 (LiGaMD2): Improved Calculations of Ligand Binding Thermodynamics and Kinetics with Closed Protein Pocket. Journal of Chemical Theory and Computation, 2023, 19, 733-745.	2.3	10
920	Recent advances and challenges in peptide drug development. , 2023, , 297-310.		1
921	Mining big data in drug discoveryâ€”triaging and decision trees. , 2023, , 265-281.		1
922	Recent Advances in Biomolecular NMR for Drug Discovery. , 2012, , 254-270.		0
923	Drug discovery: Standing on the shoulders of giants. , 2023, , 207-338.		0
924	Biophysical Dissection of Isolated GPCRs: The Adenosine A2A Receptor under the Bistouries. , 2023, 2, 47-92.		0
925	Proteomeâ€”Wide Fragmentâ€”Based Ligand and Target Discovery. Israel Journal of Chemistry, 2023, 63, .	1.0	1
926	DrugEx v3: scaffold-constrained drug design with graph transformer-based reinforcement learning. Journal of Cheminformatics, 2023, 15, .	2.8	11
927	The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation. ChemMedChem, 2023, 18, .	1.6	3
928	Twoâ€”Step Validation Approach for Tools To Study the DNA Repair Enzyme SNM1A. ChemBioChem, 2023, 24, .	1.3	1
929	Predicting Biomolecular Binding Kinetics: A Review. Journal of Chemical Theory and Computation, 2023, 19, 2135-2148.	2.3	10
932	Fragment-based Ligand Discovery (FBLD). , 2023, , 188-230.		0
935	The impact of artificial intelligence methods on drug design. , 2023, , 89-137.		0
936	Structure-based methods in drug design. , 2023, , 205-237.		0
937	Nucleic acids as templates and catalysts in chemical reactions: target-guided dynamic combinatorial chemistry and <i>in situ</i> click chemistry and DNA/RNA induced enantioselective reactions. Chemical Society Reviews, 2023, 52, 4248-4291.	18.7	2



#	ARTICLE	IF	CITATIONS
941	Target-Based Screening for Lead Discovery. , 2023, , 141-173.		0
945	Drug Design Methods to Regulate Protein-Protein Interactions. , 2023, , 265-341.		0
949	MiDi: Mixed Graph and 3D Denoising Diffusion for Molecule Generation. Lecture Notes in Computer Science, 2023, , 560-576.	1.0	1
951	Artificial Intelligence Generative Chemistry Design of Target-Specific Scaffold-Focused Small Molecule Drug Libraries. , 2023, , 503-521.		0
953	Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil. Neuroscience Bulletin, 0, , .	1.5	0
954	Protein-Protein Interaction for Drug Discovery. Engineering Materials, 2024, , 255-269.	0.3	0
956	Molecular fragmentation as a crucial step in the AI-based drug development pathway. Communications Chemistry, 2024, 7, .	2.0	0
957	Screening-Technologien zur Leitstruktursuche. , 2023, , 107-127.		0